<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
<journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLoS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28248968</article-id>
<article-id pub-id-type="pmc">5332030</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0172189</article-id>
<article-id pub-id-type="publisher-id">PONE-D-16-37443</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Database and Informatics Methods</subject>
<subj-group>
<subject>Bioinformatics</subject>
<subj-group>
<subject>Sequence Analysis</subject>
<subj-group>
<subject>Sequence Motif Analysis</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Genetic Loci</subject>
<subj-group>
<subject>Alleles</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Database and Informatics Methods</subject>
<subj-group>
<subject>Biological Databases</subject>
<subj-group>
<subject>Mutation Databases</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Mutation</subject>
<subj-group>
<subject>Mutation Databases</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Research and Analysis Methods</subject>
<subj-group>
<subject>Database and Informatics Methods</subject>
<subj-group>
<subject>Biological Databases</subject>
<subj-group>
<subject>Genomic Databases</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Computational Biology</subject>
<subj-group>
<subject>Genome Analysis</subject>
<subj-group>
<subject>Genomic Databases</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Genetics</subject>
<subj-group>
<subject>Genomics</subject>
<subj-group>
<subject>Genome Analysis</subject>
<subj-group>
<subject>Genomic Databases</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Proteins</subject>
<subj-group>
<subject>Protein Interactions</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Molecular Biology</subject>
<subj-group>
<subject>Macromolecular Structure Analysis</subject>
<subj-group>
<subject>Protein Structure</subject>
<subj-group>
<subject>Protein Structure Prediction</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and Life Sciences</subject>
<subj-group>
<subject>Biochemistry</subject>
<subj-group>
<subject>Proteins</subject>
<subj-group>
<subject>Protein Structure</subject>
<subj-group>
<subject>Protein Structure Prediction</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Physical Sciences</subject>
<subj-group>
<subject>Chemistry</subject>
<subj-group>
<subject>Chemical Compounds</subject>
<subj-group>
<subject>Organic Compounds</subject>
<subj-group>
<subject>Amines</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Physical Sciences</subject>
<subj-group>
<subject>Chemistry</subject>
<subj-group>
<subject>Organic Chemistry</subject>
<subj-group>
<subject>Organic Compounds</subject>
<subj-group>
<subject>Amines</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
<subj-group subj-group-type="Discipline-v3">
<subject>Biology and life sciences</subject>
<subj-group>
<subject>Cell biology</subject>
<subj-group>
<subject>Signal transduction</subject>
<subj-group>
<subject>Cell signaling</subject>
<subj-group>
<subject>Signaling cascades</subject>
<subj-group>
<subject>MAPK signaling cascades</subject>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Genomic variants reveal differential evolutionary constraints on human transglutaminases and point towards unrecognized significance of transglutaminase 2</article-title>
<alt-title alt-title-type="running-head">Genomic variants in human transglutaminases</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Thangaraju</surname>
<given-names>Kiruphagaran</given-names>
</name>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Király</surname>
<given-names>Róbert</given-names>
</name>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Demény</surname>
<given-names>Máté A.</given-names>
</name>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>András Mótyán</surname>
<given-names>János</given-names>
</name>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fuxreiter</surname>
<given-names>Mónika</given-names>
</name>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fésüs</surname>
<given-names>László</given-names>
</name>
<xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label>
<addr-line>Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary</addr-line></aff>
<aff id="aff002"><label>2</label>
<addr-line>MTA-DE Momentum Laboratory of Protein Dynamics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary</addr-line></aff>
<aff id="aff003"><label>3</label>
<addr-line>MTA-DE Stem cell, Apoptosis and Genomics Research Group of Hungarian Academy of Sciences, Faculty of Medicine, University of Debrecen, Debrecen, Hungary</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Eckert</surname>
<given-names>Richard L.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"></xref>
</contrib>
</contrib-group>
<aff id="edit1">
<addr-line>University of Maryland School of Medicine, UNITED STATES</addr-line>
</aff>
<author-notes>
<fn fn-type="COI-statement" id="coi001">
<p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple"><list-item><p><bold>Conceptualization:</bold> LF.</p></list-item><list-item><p><bold>Formal analysis:</bold> KT RK.</p></list-item><list-item><p><bold>Funding acquisition:</bold> LF RK MF.</p></list-item><list-item><p><bold>Methodology:</bold> LF KT.</p></list-item><list-item><p><bold>Software:</bold> MF JAM MAD.</p></list-item><list-item><p><bold>Writing – original draft:</bold> LF KT MF MAD.</p></list-item></list>
</p>
</fn>
<corresp id="cor001">* E-mail: <email>fesus@med.unideb.hu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>1</day>
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>12</volume>
<issue>3</issue>
<elocation-id>e0172189</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>9</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>2</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© 2017 Thangaraju et al</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>Thangaraju et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="pone.0172189.pdf"></self-uri>
<abstract>
<p>Transglutaminases (TGMs) catalyze Ca<sup>2+</sup>-dependent transamidation of proteins with specified roles in blood clotting (F13a) and in cornification (TGM1, TGM3). The ubiquitous TGM2 has well described enzymatic and non-enzymatic functions but in-spite of numerous studies its physiological function in humans has not been defined. We compared data on non-synonymous single nucleotide variations (nsSNVs) and loss-of-function variants on TGM1-7 and F13a from the Exome aggregation consortium dataset, and used computational and biochemical analysis to reveal the roles of damaging nsSNVs of TGM2. TGM2 and F13a display rarer damaging nsSNV sites than other TGMs and sequence of TGM2, F13a and TGM1 are evolutionary constrained. TGM2 nsSNVs are predicted to destabilize protein structure, influence Ca<sup>2+</sup> and GTP regulation, and non-enzymatic interactions, but none coincide with conserved functional sites. We have experimentally characterized six TGM2 allelic variants detected so far in homozygous form, out of which only one, p.Arg222Gln, has decreased activities. Published exome sequencing data from various populations have not uncovered individuals with homozygous loss-of-function variants for TGM2, TGM3 and TGM7. Thus it can be concluded that human transglutaminases differ in harboring damaging variants and TGM2 is under purifying selection suggesting that it may have so far not revealed physiological functions.</p>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>Research grant of the University of Debrecen</institution>
</funding-source>
<award-id>RH/885/2013</award-id>
<principal-award-recipient>
<name>
<surname>Király</surname>
<given-names>Róbert</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003549</institution-id>
<institution>Országos Tudományos Kutatási Alapprogramok</institution>
</institution-wrap>
</funding-source>
<award-id>OTKA NK 105046</award-id>
<principal-award-recipient>
<name>
<surname>Fésüs</surname>
<given-names>László</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award003">
<funding-source>
<institution>New Hungary Development Plan</institution>
</funding-source>
<award-id>TÁMOP-4.2.2.A-11/1/KONV-2012-0023 “VÉD-ELEM”</award-id>
<principal-award-recipient>
<name>
<surname>Fésüs</surname>
<given-names>László</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award004">
<funding-source>
<institution>European Union Framework Programme 7 TRANSPATH ITN</institution>
</funding-source>
<award-id>289964</award-id>
<principal-award-recipient>
<name>
<surname>Fésüs</surname>
<given-names>László</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award005">
<funding-source>
<institution>European Union and the State of Hungary, co-financed by the European Social Fund</institution>
</funding-source>
<award-id>TÁMOP 4.2.4. A/2-11-1-2012-0001 ‘National Excellence Programme’</award-id>
<principal-award-recipient>
<name>
<surname>Király</surname>
<given-names>Róbert</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award006">
<funding-source>
<institution-wrap>
<institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100003549</institution-id>
<institution>Országos Tudományos Kutatási Alapprogramok</institution>
</institution-wrap>
</funding-source>
<award-id>OTKA NN 106562</award-id>
<principal-award-recipient>
<name>
<surname>Fuxreiter</surname>
<given-names>Mónika</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award007">
<funding-source>
<institution>Momentum program of the Hungarian Academy of Sciences</institution>
</funding-source>
<award-id>LP2012-41</award-id>
<principal-award-recipient>
<name>
<surname>Fuxreiter</surname>
<given-names>Mónika</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This work was supported by the Research University Grant of the University of Debrecen (RH/885/2013) (RK), the Hungarian Scientific Research Fund (OTKA NK 105046) (LF), the New Hungary Development Plan via the TÁMOP-4.2.2.A-11/1/KONV- 2012-0023 “VÉD-ELEM” project co-financed by the European Social Fund (LF), the European Union Framework Programme 7 TRANSPATH ITN 289964 (LF KT) and the European Union and the State of Hungary, co-financed by the European Social Fund in the framework of the TÁMOP 4.2.4. A/2-11-1-2012-0001 ‘National Excellence Programme’ (RK). The support of the Hungarian Scientific Research Fund (OTKA NN 106562) and the Momentum programme (LP2012-41) of the Hungarian Academy of Sciences is gratefully acknowledged (MF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="5"></table-count>
<page-count count="24"></page-count>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All data used in this study are publicly available from from the NCBI Online Mendelian Inheritance in Man (OMIM) database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/omim">https://www.ncbi.nlm.nih.gov/omim</ext-link>) under accession numbers 134570 (F13a), 190195 (TGM1), 603805 (TGM5), and 613900 (TGM6). The accession numbers used for transglutaminases (TGM) from the Exome Aggregation Consortium (ExAC) database (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/">http://exac.broadinstitute.org/</ext-link>) are given here. F13A: 6:6144318-6321246, TGM1: 14:24718320-24733638, TGM2: 20:36756863-36794980, TGM3: 20:2276647-2321724, TGM4: 3:44916100-44956482, TGM5: 15:43524793-43559055, TGM6: 20:2361554-2413399, TGM7: 15:43568478-43594453.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<title>Data Availability</title>
<p>All data used in this study are publicly available from from the NCBI Online Mendelian Inheritance in Man (OMIM) database (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/omim">https://www.ncbi.nlm.nih.gov/omim</ext-link>) under accession numbers 134570 (F13a), 190195 (TGM1), 603805 (TGM5), and 613900 (TGM6). The accession numbers used for transglutaminases (TGM) from the Exome Aggregation Consortium (ExAC) database (<ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/">http://exac.broadinstitute.org/</ext-link>) are given here. F13A: 6:6144318-6321246, TGM1: 14:24718320-24733638, TGM2: 20:36756863-36794980, TGM3: 20:2276647-2321724, TGM4: 3:44916100-44956482, TGM5: 15:43524793-43559055, TGM6: 20:2361554-2413399, TGM7: 15:43568478-43594453.</p>
</notes>
</front>
<body>
<sec id="sec001" sec-type="intro">
<title>Introduction</title>
<p>Transglutaminases (TGM) are a family of Ca<sup>2+</sup>-dependent protein transamidating and cross-linking enzymes implicated in variety of biological processes. So far eight active and one inactive member (F13a, TGM1-TGM7, and Band 4.2) have been identified in humans. F13a plays a pivotal role in blood coagulation by crosslinking fibrin, TGM1 is essential for proper cornification in the skin with contribution from TGM3 and TGM5, and TGM4 seems to have a role in prostate function [<xref ref-type="bibr" rid="pone.0172189.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0172189.ref002">2</xref>]. The role of TGM6 and TGM7 are not known. The most studied TGM2 is widely expressed exhibiting transamidase, isopeptidase, protein disulphide isomerase, protein kinase, GTP and ATP binding and hydrolyzing activities [<xref ref-type="bibr" rid="pone.0172189.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0172189.ref002">2</xref>]. Its transamidase activity is reciprocally regulated by GTP and Ca<sup>2+</sup> binding, which are followed by a large conformational change resulting in either an inactive closed or a potentially active opened conformation, respectively [<xref ref-type="bibr" rid="pone.0172189.ref003">3</xref>]. TGM2 interacts with many other interacting partners including fibronectin and can act as a protein scaffold (reviewed in [<xref ref-type="bibr" rid="pone.0172189.ref004">4</xref>]). TGM2 is involved in a broad range of cellular processes (including transmembrane signaling, mitochondrial functions, gene expression regulation, autophagy, and apoptosis) and has been related to pathological conditions such as inflammation, autoimmune disease, cancer progression, and neurodegenerative disorders (reviewed in [<xref ref-type="bibr" rid="pone.0172189.ref005">5</xref>]). TGM2 knock out mice are born and live without any obvious phenotype—although they have decreased defense to some environmental stress and diseases which develop by age (reviewed in [<xref ref-type="bibr" rid="pone.0172189.ref005">5</xref>, <xref ref-type="bibr" rid="pone.0172189.ref006">6</xref>]). Understanding the physiological functions of TGM2 in humans is still awaited since no TGM2 deficiency or dominant TGM2 mutant has been observed and systematic inhibitor studies could not be carried out.</p>
<p>After the completion of the human genome project and large scale exome sequencing presented in various databases, it has become evident that vast majority of our proteins are polymorphic to various genomic changes including single nucleotide variations and loss-of-function alterations. Rapid population growth coupled with inefficient and weak natural selection has led to excessive rare variants in our genome, some are associated with severe pathological phenotypes as a result of damaging mutations [<xref ref-type="bibr" rid="pone.0172189.ref007">7</xref>]. They can affect protein function and are implicated in both Mendelian and complex diseases [<xref ref-type="bibr" rid="pone.0172189.ref008">8</xref>]. In general, out of 13,000 exonic variants present per person, about 60% are non-synonymous [<xref ref-type="bibr" rid="pone.0172189.ref009">9</xref>]. Non-synonymous single nucleotide variants (nsSNVs) located in protein cores and protein-protein interfaces are disease-causing [<xref ref-type="bibr" rid="pone.0172189.ref009">9</xref>] owing to protein misfolding or instability or altered protein-protein interactions. Recent whole-genome and exome sequencing data from different populations, including bottlenecked and consanguineous ones, have revealed a large number of genes with homozygous or compound heterozygous loss-of-function (LOF) variants leading to human knockouts and efforts are underway to find phenotypic consequences of these knockouts [<xref ref-type="bibr" rid="pone.0172189.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>, <xref ref-type="bibr" rid="pone.0172189.ref012">12</xref>]. In addition, new genome editing technologies made it possible to knock out human protein coding genes one by one and to test which are essential for cell proliferation and survival in culture highlighting approximately 2000 such genes [<xref ref-type="bibr" rid="pone.0172189.ref013">13</xref>, <xref ref-type="bibr" rid="pone.0172189.ref014">14</xref>, <xref ref-type="bibr" rid="pone.0172189.ref015">15</xref>].</p>
<p>We noticed earlier in limited exome sequence data sets that the protein coding sequence of human TGM2 has the lowest variability when compared to other members of the transglutaminase family [<xref ref-type="bibr" rid="pone.0172189.ref016">16</xref>]. In the present study we analyzed large scale population genomics data in an effort to understand evolutionary forces that have shaped this family of enzymes in human populations. We have screened the Exome Aggregation Consortium (ExAC) database for single nucleotide variant types in the transglutaminase family and compared the TGM2 variants with other members of the family. We focused on the potential impact of damaging TGM2 nsSNVs on protein stability, secondary structure, functional sites including calcium, fibronectin and GTP binding sites. We also studied intrinsically disordered regions (IDRs) which affect protein dynamics and could interfere with conformational changes as well as harbor short linear motifs (SLiMs) for protein interactions and modifications. To this aim, the evolutionary constraints on TGMs and population frequencies of the homozygous transglutaminase nsSNVs have been compared. The homozygote allele variants with nsSNVs available in public datasets were produced, analyzed and tested in biochemical assays. We have also searched for data to see the prevalence of transglutaminase LOF variants and human knock outs as well as disease causing mutations in different populations to see how essential these proteins are for humans.</p>
</sec>
<sec id="sec002" sec-type="materials|methods">
<title>Materials and methods</title>
<p>All materials were purchased from Sigma (St Louis, MO, USA) unless otherwise indicated. The FLpepT26 peptide was obtained as published in Ref. [<xref ref-type="bibr" rid="pone.0172189.ref017">17</xref>] and S100A4 (GST) as published in Ref. [<xref ref-type="bibr" rid="pone.0172189.ref018">18</xref>].</p>
<sec id="sec003">
<title>Databases</title>
<p>For single nucleotide variation data we used the Exome Aggregation Consortium browser (beta version) ([<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>]; Exome aggregation consortium (ExAC), Cambridge, MA (URL: <ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/">http://exac.broadinstitute.org/</ext-link>) accessed August 2016). The ExAC is a coalition of investigators seeking to aggregate and harmonize exome sequencing data from a wide variety of large-scale sequencing projects, and to make summary data available for the wider scientific community. The data set provided on the above mentioned website spans 60,706 unrelated individuals sequenced as part of various disease-specific and population genetic studies and 17 projects contribute to the data.</p>
<p>Short linear motifs were identified using the Eukaryotic Linear Motif (ELM) resource [<xref ref-type="bibr" rid="pone.0172189.ref019">19</xref>]. For information about catalogue of human mutations and related genetic disorders, the Online Mendelian Inheritance in Man<sup>®</sup> was used (Online Mendelian Inheritance in Man, OMIM<sup>®</sup>. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD), {07/16/2016}. World Wide Web URLs: <ext-link ext-link-type="uri" xlink:href="http://omim.org/">http://omim.org/</ext-link>). MIM Numbers and accession dates: F13a: {134570}{07/16/2016}; TGM1: {190195}{07/16/2016}; TGM5: {603805}{07/16/2016}; TGM6: {613900}{05/08/2016}. This article only uses anonymous human data from freely available public databases that have been obtained in a manner conforming to the respective IRB and/or granting agency ethical guidelines.</p>
<p>The mis_z scores were taken from the ExAC dataset [<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>]. In order to create a constraint metric and to contrast observed and expected number of variants per gene, mis_z scores were calculated. The mis_z score is based on a previous mutational model of probabilities of mutation for regional genomic divergence between humans and macaques [<xref ref-type="bibr" rid="pone.0172189.ref020">20</xref>] but with some modifications [<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>]. In Lek et al. [<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>] instead of probability of mutation, the expected number of variants were adjusted for depth of sequencing coverage for each exon. This depth adjusted correction was implemented to account for poorly sequenced regions with fewer variants than expectation. Across canonical transcripts all exon level variant counts were added and then a chi-squared value (Chi-square is a statistical test commonly used to compare observed data with data one would expect to obtain according to a specific hypothesis) for each mutational types (synonymous, missense, and protein-truncating) was calculated. If the observed variants are smaller than expected the square root of the chi-squared values were multiplied by 1 and if the observed variants are greater than expected then the values were multiplied by -1 to create a Z score. Finally, a corrected missense z score was created by dividing all missense z scores by standard deviation of the mirrored distribution. Mirrored or Gumbel distribution is an Extreme Value distribution Type-I; it is used for modelling extreme values of a random variable when the mean of smaller and larger values are farther apart.</p>
<p>Gene damage index (GDI) scores were taken from [<xref ref-type="bibr" rid="pone.0172189.ref021">21</xref>]. GDI is a metric which defines the non-synonymous mutational load in each protein-coding gene in the general population [<xref ref-type="bibr" rid="pone.0172189.ref021">21</xref>]. The damage caused to the exonic regions of the gene was predicted by calculating GDI score for each human gene g with n minor alleles (minor allele frequency &lt; 0.5). For Phred I-score the ranking of the gene of interest i relative to all other human genes T = 19,558 genes, with values ranging from 0 (lowest Phred) to 42.91 (highest Phred) was calculated: I<sub>i</sub> = −10[log 10(i/T)].</p>
</sec>
<sec id="sec004">
<title>Bioinformatic tools</title>
<p>To predict the possible impact of single amino acid substitutions on the structure and function of a human protein, Polymorphism Phenotyping (PolyPhen) and Sorting Intolerant From Tolerant (SIFT) analyses were applied for nsSNVs in the ExAC database. If more than one change is present at an amino acid residue and both having same scores, PANTHER (Protein ANalysis THrough Evolutionary Relationships) prediction was carried out to determine which of the two was the damaging nsSNV [<xref ref-type="bibr" rid="pone.0172189.ref022">22</xref>]. The deleterious, possibly or probably damaging nsSNVs are mentioned as damaging in the text.</p>
<p>GORIV was used to predict the secondary structures (<ext-link ext-link-type="uri" xlink:href="https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_gor4.html">https://npsa-prabi.ibcp.fr/cgi-bin/npsa_automat.pl?page=/NPSA/npsa_gor4.html</ext-link> accessed on 15 March 2016) of wild type and mutant human TGM2 proteins. Stability analysis was performed by algorithm FoldX [<xref ref-type="bibr" rid="pone.0172189.ref023">23</xref>] using default parameters of the program. Changes in the overall stability of the proteins (ΔΔG [kcal/mol]) for damaging nsSNVs were calculated in both opened (PDB ID: 2Q3Z) and closed (PDB ID: 1KV3) forms. TGM2 involving residues 1–14 and 323–326 for which the coordinates in either or both crystal structures are not available were excluded from the stability analysis.</p>
</sec>
<sec id="sec005">
<title>Homology modelling of TGM2</title>
<p>Homology models of TGM2 to represent one Ca<sup>2+</sup> and a three Ca<sup>2+</sup>-bound states were built with SWISS-MODEL using the X-ray crystal structures of either FXIIIa (pdb: 4KTY) or TGM3 (pdb: 1L9M), respectively, as templates [<xref ref-type="bibr" rid="pone.0172189.ref024">24</xref>, <xref ref-type="bibr" rid="pone.0172189.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0172189.ref026">26</xref>]. The models were then repaired for energy minimization using the FoldX forcefield. The R222 residue was mutated to glutamine using FoldX and the structures were visualized with the help of the FoldX plugin in YASARA [<xref ref-type="bibr" rid="pone.0172189.ref027">27</xref>, <xref ref-type="bibr" rid="pone.0172189.ref028">28</xref>]. Figures were prepared using PyMol Molecular Graphics System (version 1.8 Schrödinger LLC).</p>
</sec>
<sec id="sec006">
<title>Transglutaminase enzyme preparations</title>
<p>The TGM2 variants were constructed using the QuikChange II Site-Directed Mutagenesis Kit Manual (Stratagene, La Jolla, California, USA) and were checked by restriction analysis and DNA sequencing (Capillary sequencing runs were performed by Genomic Medicine and Bioinformatics Core Facility at University of Debrecen). Wild-type TGM2 and homozygous nonsynonymous variants were expressed in N-terminally (His)<sub>6</sub>-tagged form (pET-30 Ek/LIC-TGM2) and purified by Ni-NTA affinity chromatography as described previously [<xref ref-type="bibr" rid="pone.0172189.ref029">29</xref>]. The protein concentrations were determined based on Bradford method (Bio-Rad Protein Assay, Bio-Rad, München, Germany). Finally, protein purity was checked after staining of SDS-polyacrylamide gels by PageBlue Protein Staining Solution (Thermo Fisher Scientific, Waltham, Massachusetts, USA). GenBank Accession Number of the wild-type TGM2 used in this study: RefSeq NM_004613. The dbSNP identifiers of the TGM2 homozygous nonsynonymous variants: p.Arg76His (rs41274720), p.Arg222Gln (rs200551434), p.Arg433Gln (rs142184177), p.Val542Phe (rs115436227), p.Pro612Thr (rs199563008), p.Asp671Asn (rs141236503).</p>
</sec>
<sec id="sec007">
<title>Transamidase assays</title>
<p>The kinetic amine incorporation assay was performed with slight modification of a previously published procedure [<xref ref-type="bibr" rid="pone.0172189.ref029">29</xref>]: The reaction mixture contained 50 mM Tris-HCl buffer pH 7.5, 0.5 mM dansyl-cadaverine, 2 mg/ml N,N’ dimethylated casein, 3 mM DTT, and 3 mM CaCl<sub>2</sub> or 10 mM EDTA. The reaction volume was 100 μl and the assay was started with the addition of 20 μl enzyme (100 nM TGM2 final concentration). The reaction rate was calculated based on the initial slopes of the kinetic curves (Ex/Em: 360/490 nm; at 37°C) using GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla, California USA, <ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/">www.graphpad.com</ext-link>).</p>
<p>A real time fluorescence anisotropy assay was also used to measure the crosslinking activity [<xref ref-type="bibr" rid="pone.0172189.ref017">17</xref>]. The crosslinking of FLpepT26 into S100A4 (GST) by TGM2 was monitored by increase in the fluorescence anisotropy. The volume of the reaction mixture was 35 μl and performed for 30 mins at 37°C with 100 nM FLpepT26, 13.15 μM S100A4 (GST), 10 nM TG2, and 3 mM CaCl<sub>2</sub> (5 mM EDTA was used as negative control). The reaction buffer contained 20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 5 mM DTT, and 0.01% Tween 20. A 384-well untreated Polystyrene Black Microplate was used (Nunc, Thermo Scientific, Denmark, cat. no. 262260) and the change of the fluorescence anisotropy was measured by Synergy H1 microplate reader (GreenFP filter cube, excitation 485 nm, emission 528 nm; BioTek, Winooski, VT, USA). The reaction rate was calculated from the initial slopes of the kinetic curves using GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla California, USA, <ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/">www.graphpad.com</ext-link>).</p>
</sec>
<sec id="sec008">
<title>Isopeptidase assays</title>
<p>The basis of the Zedira assay is that transglutaminase cleaves the isopeptide bond in the synthesized substrate releasing the dark quencher (2, 4-dinitrophenyl) linked to the cadaverine spacer followed by the increase of fluorescence from the N-terminally attached fluorophore 2-aminobenzoyl (2-Abz). The reaction was performed based on previously published method [<xref ref-type="bibr" rid="pone.0172189.ref029">29</xref>]. In detail the reaction mixture was: 50 mM MOPS buffer, pH 6.8, containing 5 mM CaCl<sub>2</sub>, 100 mM NaCl, 0.1% (w/v) PEG8000, 100 nM TGM2, 50 μM A102 isopeptidase assay substrate (Zedira, Darmstadt, Germany), and 2.8 mM DTT (added with the starting solution which contained the enzyme). The reaction was monitored at 37°C by a Synergy H1 microplate reader (Ex/Em: 318/413 nm) and the activities were calculated from the initial slopes of the kinetic curves.</p>
<p>The isopeptidase assay using novel crosslinked protein–peptide substrate was carried out using previously published real-time fluorescence method [<xref ref-type="bibr" rid="pone.0172189.ref018">18</xref>]. The cleavage of the isopeptide bond on FLpepT26–S100A4 (GST) substrate by TGM2 was followed by decrease in fluorescence anisotropy. The volume of the reaction was 35 μl and performed for 60 mins at 37°C with 0.5 μM FLpepT26–S100A4 (GST), 300 nM TGM2, and 5 mM CaCl<sub>2</sub> or EDTA. The reaction buffer contained 20 mM MOPS (pH 6.8), 150 mM NaCl, 6 mM glycine methyl ester, 5 mM DTT, and 0.1% Tween 20. A 384-well untreated Polystyrene Black Microplates (Nunc, Thermo Scientific, Denmark, cat. no. 262260) and Synergy H1 microplate reader (GreenFP filter cube, excitation 485 nm, emission 528 nm; BioTek, Winooski, VT, USA) was used to measure changes of fluorescence anisotropy. The reaction rates were calculated from the initial slopes of the kinetic curves in terms of anisotropy per minute using GraphPad Prism version 7.00 for Windows (GraphPad Software, La Jolla California USA, <ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com/">www.graphpad.com</ext-link>).</p>
</sec>
<sec id="sec009">
<title>BODIPY FL GTPγS nucleotide binding assay</title>
<p>500 nM BODIPY FL GTPγS, (Invitrogen, Carlsbad, CA, United States) [<xref ref-type="bibr" rid="pone.0172189.ref029">29</xref>] a GTP analog was used to compare nucleotide binding to increasing amounts of TGM2 variants in the presence of 20 mM HEPES pH 7.5, 150 mM NaCl, 0.1 mM TCEP, 0.05% Tween-20, 0.1 mM EGTA, and 1 mM MgCl<sub>2</sub>. There is an increase in fluorescence when BODIPY FL GTPγS binds to GTP-binding proteins providing a non-radioactive alternative tool to analyse protein-nucleotide interactions.</p>
</sec>
<sec id="sec010">
<title>Fibronectin binding assay</title>
<p>The fibronectin-binding property of the variants was tested using a previously published direct ELISA assay [<xref ref-type="bibr" rid="pone.0172189.ref016">16</xref>] with the following modifications. After fibronectin coating and washing, 0.3 μg TGM2 wild-type or variant was incubated in each well for 1 h at room temperature in TTBS buffer containing 2.5 mM CaCl<sub>2</sub>. The amount of bound TGM2 variants were detected using CUB7402 (1:5,000, Neo markers, Fremont, CA) monoclonal antibodies and then anti-mouse IgG/ HRP (1:7,500) with TMB substrate at 450 nm.</p>
</sec>
</sec>
<sec id="sec011" sec-type="results">
<title>Results</title>
<sec id="sec012">
<title>Synonymous, non-synonymous and LOF nucleotide variants in genes of the human transglutaminase family</title>
<p>Recent advances in next-generation sequencing technologies and initiatives such as the 1000 Genomes and other exome sequencing projects have uncovered a broad range of genetic variations among individuals. For analysis of variants in the transglutaminase enzyme family the ExAC database was chosen as a source of SNV data. As of August 2016 it contained high quality exon sequencing data from 60,706 unrelated individuals displaying one variant at every eight bases [<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>]. There were 5,766 SNV entries for transglutaminases of which 3623 SNVs fall under synonymous, non-synonymous or LOF categories in exons (<xref ref-type="table" rid="pone.0172189.t001">Table 1</xref>). Out of the total entries only 4.5–6% of SNVs in case of each family were non-synonymous SNVs. TGM2, TGM4, TGM5 had the lowest and TGM6 had the highest number of nsSNVs (<xref ref-type="table" rid="pone.0172189.t001">Table 1</xref>). The range of loss-of-function (LOF; including frameshift, splice acceptor and stop gained) variants were from 19 in TGM1 to 40 in TGM5, while TGM2 had 29 LOF variants (<xref ref-type="table" rid="pone.0172189.t001">Table 1</xref>). The number and percentage of residues polymorphic to nsSNVs in each family was also calculated. F13a, TGM1, TGM2, and TGM5 had less percent of such residues while TGM3 and TGM6 had the highest (<xref ref-type="fig" rid="pone.0172189.g001">Fig 1A</xref>).</p>
<fig id="pone.0172189.g001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172189.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Analyses of non-synonymous variants in the transglutaminase family.</title>
<p><bold>(A) Amino acid residues polymorphic to non-synonymous variants.</bold> The percentage of polymorphic residues was obtained as a ratio of the total number of amino acid residues polymorphic to nsSNVs and the sequence length. The percentage of polymorphic residues is shown. <bold>(B</bold>) <bold>Proportion of damaging and benign non-synonymous variants by the PolyPhen score.</bold> Ratio of damaging nsSNVs: F13a (42.8%), TGM1 (60.8%), TGM2 (43.7%), TGM3 (52.2%), TGM4 (51%), TGM5 (55.3%), TGM6 (52.5%), and TGM7 (49.5%). <bold>(C) Location of damaging nsSNVs in amino acid sequence of TGM2 by PolyPhen/SIFT scores.</bold> Lane 1: sequence of human TGM2, Lane 2: damaging nsSNVs in human TGM2. Functional regions of human TGM2: Intrinsically disordered regions (dark red) [<xref ref-type="bibr" rid="pone.0172189.ref004">4</xref>], amino acid clusters in light blue [<xref ref-type="bibr" rid="pone.0172189.ref030">30</xref>], fibronectin binding sites (FN) (green) K30, R116, and H134 [<xref ref-type="bibr" rid="pone.0172189.ref031">31</xref>], GDP binding residues (orange) S171, K173, R476, R478, V479, R580, Y583 [<xref ref-type="bibr" rid="pone.0172189.ref032">32</xref>], catalytic residues (pink); non-canonical Ca<sup>2+</sup>-binding sites: S4: 149–159, S1: 228–236, S3A: 305–311, S3B: 326–333, S2A: 395–401, S5: 432–440, and S2B: 445–455 (underlined and bolded) [<xref ref-type="bibr" rid="pone.0172189.ref033">33</xref>]. Domains of human TGM2 are presented vertically: β sandwich (1–139), catalytic core (147–460), β-barrel 1 (472–583), and β-barrel 2 (584–687).</p>
</caption>
<graphic xlink:href="pone.0172189.g001"></graphic>
</fig>
<table-wrap id="pone.0172189.t001" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172189.t001</object-id>
<label>Table 1</label>
<caption>
<title>Number of different single nucleotide variants and gene constraints in human transglutaminase genes.</title>
</caption>
<alternatives>
<graphic id="pone.0172189.t001g" xlink:href="pone.0172189.t001"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="1" rowspan="1">Gene</th>
<th align="center" colspan="1" rowspan="1">Synonymous</th>
<th align="center" colspan="1" rowspan="1">Non-synonymous</th>
<th align="center" colspan="1" rowspan="1">Loss-of-Function</th>
<th align="center" colspan="1" rowspan="1">n_mis</th>
<th align="center" colspan="1" rowspan="1">exp_mis</th>
<th align="center" colspan="1" rowspan="1">mis_z</th>
<th align="center" colspan="1" rowspan="1">GDI</th>
<th align="center" colspan="1" rowspan="1">GDI-Phred I</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1">F13a</td>
<td align="center" colspan="1" rowspan="1">120</td>
<td align="center" colspan="1" rowspan="1">283</td>
<td align="center" colspan="1" rowspan="1">22</td>
<td align="center" colspan="1" rowspan="1">252</td>
<td align="center" colspan="1" rowspan="1">269.8</td>
<td align="center" colspan="1" rowspan="1">0.53</td>
<td align="center" colspan="1" rowspan="1">4254.7</td>
<td align="center" colspan="1" rowspan="1">12.9</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM1</td>
<td align="center" colspan="1" rowspan="1">163</td>
<td align="center" colspan="1" rowspan="1">320</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">314</td>
<td align="center" colspan="1" rowspan="1">349.2</td>
<td align="center" colspan="1" rowspan="1">0.92</td>
<td align="center" colspan="1" rowspan="1">277.2</td>
<td align="center" colspan="1" rowspan="1">3.5</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM2</td>
<td align="center" colspan="1" rowspan="1">148</td>
<td align="center" colspan="1" rowspan="1">272</td>
<td align="center" colspan="1" rowspan="1">29</td>
<td align="center" colspan="1" rowspan="1">270</td>
<td align="center" colspan="1" rowspan="1">290.5</td>
<td align="center" colspan="1" rowspan="1">0.59</td>
<td align="center" colspan="1" rowspan="1">240.6</td>
<td align="center" colspan="1" rowspan="1">3.3</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM3</td>
<td align="center" colspan="1" rowspan="1">144</td>
<td align="center" colspan="1" rowspan="1">313</td>
<td align="center" colspan="1" rowspan="1">20</td>
<td align="center" colspan="1" rowspan="1">304</td>
<td align="center" colspan="1" rowspan="1">271.9</td>
<td align="center" colspan="1" rowspan="1">-0.95</td>
<td align="center" colspan="1" rowspan="1">1529.8</td>
<td align="center" colspan="1" rowspan="1">7.2</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM4</td>
<td align="center" colspan="1" rowspan="1">121</td>
<td align="center" colspan="1" rowspan="1">279</td>
<td align="center" colspan="1" rowspan="1">39</td>
<td align="center" colspan="1" rowspan="1">264</td>
<td align="center" colspan="1" rowspan="1">232.6</td>
<td align="center" colspan="1" rowspan="1">-1.0</td>
<td align="center" colspan="1" rowspan="1">3544.7</td>
<td align="center" colspan="1" rowspan="1">11.4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM5</td>
<td align="center" colspan="1" rowspan="1">95</td>
<td align="center" colspan="1" rowspan="1">273</td>
<td align="center" colspan="1" rowspan="1">40</td>
<td align="center" colspan="1" rowspan="1">261</td>
<td align="center" colspan="1" rowspan="1">255.9</td>
<td align="center" colspan="1" rowspan="1">-0.15</td>
<td align="center" colspan="1" rowspan="1">2224.6</td>
<td align="center" colspan="1" rowspan="1">8.6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM6</td>
<td align="center" colspan="1" rowspan="1">136</td>
<td align="center" colspan="1" rowspan="1">336</td>
<td align="center" colspan="1" rowspan="1">39</td>
<td align="center" colspan="1" rowspan="1">320</td>
<td align="center" colspan="1" rowspan="1">287.7</td>
<td align="center" colspan="1" rowspan="1">-0.92</td>
<td align="center" colspan="1" rowspan="1">764.5</td>
<td align="center" colspan="1" rowspan="1">5.4</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM7</td>
<td align="center" colspan="1" rowspan="1">91</td>
<td align="center" colspan="1" rowspan="1">293</td>
<td align="center" colspan="1" rowspan="1">28</td>
<td align="center" colspan="1" rowspan="1">283</td>
<td align="center" colspan="1" rowspan="1">263.3</td>
<td align="center" colspan="1" rowspan="1">-0.59</td>
<td align="center" colspan="1" rowspan="1">698.4</td>
<td align="center" colspan="1" rowspan="1">5.2</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001">
<p>Number of synonymous, non-synonymous and LOF variants were determined based on data available in ExAC database. The n_mis, and exp_mis scores [<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>], and GDI and GDI-Phred I values [<xref ref-type="bibr" rid="pone.0172189.ref021">21</xref>] were taken from datasets published previously. See <xref ref-type="sec" rid="sec002">methods</xref> section for brief description and ref. [<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>] and [<xref ref-type="bibr" rid="pone.0172189.ref021">21</xref>] for detailed explanation of calculations and determination of the scores. Frameshift mutations, splice acceptor, splice donor, stop gained are included under LOF category. Definition of values and scores shown in the table is as follows. The <bold>n_mis</bold> scores: number of rare (minor allele frequency (MAF) &lt;0.1%) missense variants found in ExAC r0.3 database. The <bold>exp_mis</bold> scores: depth adjusted number of expected rare (MAF &lt;0.1%) missense variants. The <bold>mis_z</bold> scores: corrected missense z scores. The z score is a constraint metric to contrast observed and expected number of variants per gene [<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>]. The number of nsSNVs in columns 3 and 5 differ because for mis_z score calculation only nsSNVs with MAF &lt; 0.1% are taken into account (n_mis, column 5). GDI is a metric used to score accumulated mutational damage on human genes [<xref ref-type="bibr" rid="pone.0172189.ref021">21</xref>]. GDI-Phred I: the GDI ranking of the gene relative to all other human genes.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec013">
<title>TGM1, TGM2 and F13a show evolutionary constraint to non-synonymous variants</title>
<p>In order to determine the constraint on a particular gene, mis_z scores were calculated for non-synonymous variations of each gene in the ExAC dataset [<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>]. The mis_z values for the transglutaminase nsSNVs are given in <xref ref-type="table" rid="pone.0172189.t001">Table 1</xref>. Increased constraint is indicated by positive mis_z scores and decreased constraint with negative mis_z scores. TGM1, TGM2 and F13a had positive, highest mis_z scores and, therefore, they had fewer variants than expected but other members had negative mis_z scores indicating that they had more variants than expected (<xref ref-type="table" rid="pone.0172189.t001">Table 1</xref>).</p>
<p>Recently, by using gene level approach, load of disease causing mutations and mutational damage on protein-coding human genes was estimated by gene damage index scores (GDI) [<xref ref-type="bibr" rid="pone.0172189.ref021">21</xref>]. The genes with low GDI score tend to be under strong purifying selection and biologically indispensable and thus harbor fewer mutations. But those with high GDI scores are under less purifying selective pressure and are likely biologically redundant with more mutations. Based on Phred I-score, the ranking of the gene of interest i relative to all other human genes (T = 19,558 genes used in the analyses in ref [<xref ref-type="bibr" rid="pone.0172189.ref021">21</xref>]) was also calculated to estimate the damaged human genes. Lowest Phred I-score refers to least damaged human gene with lowest GDI and highest Phred I-score refers to most damaged human gene. The GDI and GDI-Phred I values are listed for transglutaminases in <xref ref-type="table" rid="pone.0172189.t001">Table 1</xref>. Among transglutaminases, TGM2 and TGM1 with lowest values are under strong selective pressure as they cannot tolerate more mutations. Mutations are tolerated by other transglutaminases, particularly TGM4 and F13a with highest Phred I-score. F13a is under less purifying selection based on the GDI values, but F13a deficiency results in bleeding disorder [<xref ref-type="bibr" rid="pone.0172189.ref034">34</xref>].</p>
</sec>
<sec id="sec014">
<title>TGM2 and F13a have lowest ratio of damaging non-synonymous SNVs</title>
<p>The SIFT and polymorphism phenotyping scores provided in the ExAC database were used. According to SIFT analysis, F13a and TGM6 have lowest and highest ratios of damaging nsSNVs, respectively (data not shown). PolyPhen analysis revealed that TGM2 and F13a have the lowest, while TGM1 and TGM5 have the highest ratios of damaging nsSNVs (<xref ref-type="fig" rid="pone.0172189.g001">Fig 1B</xref>). Around 45% of nsSNVs in TGM2 are damaging and out of these 54% are concentrated in the catalytic core domain and 17% in the β-sandwich domain (<xref ref-type="fig" rid="pone.0172189.g001">Fig 1C</xref>).</p>
</sec>
<sec id="sec015">
<title>Effect of damaging nsSNVs on TGM2 structure and function</title>
<p>The damaging nsSNVs affect the stability and biochemical functions of the native proteins [<xref ref-type="bibr" rid="pone.0172189.ref035">35</xref>]. We analyzed how rare PolyPhen or SIFT predicted damaging nsSNVs (indicated in <xref ref-type="fig" rid="pone.0172189.g001">Fig 1C</xref>) influence protein stability, secondary structure and functional sites including novel amino acid clusters, IDRs, SLiMs, and LC3 (microtubule-associated protein light chain) interacting regions (LIRs).</p>
<sec id="sec016">
<title>Influence on stability and secondary structures</title>
<p>Stability effects of mutations are crucial for understanding the sequence–structure relationships and predicting the evolutionary dynamics of proteins [<xref ref-type="bibr" rid="pone.0172189.ref036">36</xref>]. FoldX analysis to assess the impact of damaging nsSNVs on TGM2 stability was performed using both the opened (PDB ID: 2Q3Z) and closed (PDB ID: 1KV3) conformations of TGM2. Mutations had equal impact on relative stability (ΔΔG) of the opened and closed conformation. Accordingly, 24.4% of nsSNVs in the opened conformation and 28.6% in the closed conformation were found to be destabilizing (ΔΔG &gt; 1 kcal/mol), 26.7% and 23.5% were highly destabilizing (ΔΔG &gt; 3 kcal/mol) in opened and closed conformation, respectively. The highly destabilizing damaging nsSNVs are dominantly located in the catalytic core domain, in accord with the observation that mutations affecting the function of a protein are highly destabilizing [<xref ref-type="bibr" rid="pone.0172189.ref037">37</xref>].</p>
<p>Based on GORIV predictions only eight damaging nsSNVs had a minor impact on the secondary structure propensities: only the insertion of a helix-breaking proline at position 12 induced helix to coil transition (<xref ref-type="supplementary-material" rid="pone.0172189.s001">S1 Table</xref>). The persistence of secondary structures after generation of nsSNVs also underscores the stability of the human TGM2 structure. Variants, p.Arg214His and p.Trp337Leu had destabilizing ΔΔG values in the opened and closed conformations and p.Arg377His in the closed conformation (<xref ref-type="supplementary-material" rid="pone.0172189.s001">S1 Table</xref>). The ΔΔG value of p.Val283Met is highly destabilizing in the opened conformation.</p>
</sec>
<sec id="sec017">
<title>Effect on conserved functional and interaction sites</title>
<p>Damaging nsSNVs are not present at active site residues (W241, C277, H335, and D358) and at recently described novel amino acid clusters emerged in humans [<xref ref-type="bibr" rid="pone.0172189.ref030">30</xref>]. We have previously identified additional residues around the active site, which are crucial for transamidase (W278) or isopeptidase (W332) activity [<xref ref-type="bibr" rid="pone.0172189.ref029">29</xref>] and there are no damaging nsSNV at these sites either. Localization and function of TGM2 in the extracellular space is critically determined by its interaction with fibronectin; there is no nsSNVs at the recently described fibronectin binding residues in TGM2 [<xref ref-type="bibr" rid="pone.0172189.ref031">31</xref>].</p>
<p>Damaging nsSNVs p.Ser171Leu, p.Arg476Gln, and p.Arg478Cys slightly influence the GDP binding sites [<xref ref-type="bibr" rid="pone.0172189.ref032">32</xref>] and all of the described non-canonical calcium binding sites [<xref ref-type="bibr" rid="pone.0172189.ref033">33</xref>] are affected (<xref ref-type="fig" rid="pone.0172189.g001">Fig 1C</xref>). Studies indicate that non-enzymatic protein-protein interactions of TGM2 have important physiological and pathological outcomes (reviewed in [<xref ref-type="bibr" rid="pone.0172189.ref004">4</xref>]). The described interaction sites in TGM2 were checked for the presence of damaging nsSNVs. Syndecan-4, which functions as a receptor for intracellular signaling is reported to interact with sequence <sup>202</sup>KFLKNAGRDCSRRSSPVYVGR<sup>222</sup> of TGM2 [<xref ref-type="bibr" rid="pone.0172189.ref038">38</xref>, <xref ref-type="bibr" rid="pone.0172189.ref039">39</xref>] which has six nsSNVs. Likewise, interaction sites of various proteins in TGM2 enclose damaging nsSNVs: the α1-adrenoceptor interaction sites L547-I561, R564-D581, and Q633-E646 [<xref ref-type="bibr" rid="pone.0172189.ref040">40</xref>, <xref ref-type="bibr" rid="pone.0172189.ref041">41</xref>] embed eleven nsSNVs, the PLCδl interaction sequence V665-K672 [<xref ref-type="bibr" rid="pone.0172189.ref042">42</xref>, <xref ref-type="bibr" rid="pone.0172189.ref043">43</xref>] has three nsSNVs, BAX and BAK interaction sequence 204–212 [<xref ref-type="bibr" rid="pone.0172189.ref044">44</xref>] embeds one, 14-3-3 binding protein interaction sequence 209–223 [<xref ref-type="bibr" rid="pone.0172189.ref045">45</xref>] has seven nsSNVs and three SUMO motifs detected on TGM2 sequence 327–329, 364–366, and 468–470 [<xref ref-type="bibr" rid="pone.0172189.ref046">46</xref>] has two nsSNVs. Therefore, presence of nsSNVs in regions targeted by several interacting partners might influence cellular TGM2 functions in transmembrane signaling, cell adhesion, migration, Ca<sup>2+</sup> regulation of transamidation, cell death induction, and protein turnover.</p>
<p>The damaging p.Met330Arg nsSNV is among the three reported heterozygous missense mutations in the TGM2 gene associated with early-onset type 2 diabetes in a small disease cohort [<xref ref-type="bibr" rid="pone.0172189.ref047">47</xref>, <xref ref-type="bibr" rid="pone.0172189.ref048">48</xref>]. It should be noted that association of TGM2 mutations and dysfunction has not been confirmed in larger diabetes patient cohorts so far and TGM2 KO mice have no impairment in glucose-stimulated insulin secretion by pancreatic islets relative to wild-type littermates [<xref ref-type="bibr" rid="pone.0172189.ref006">6</xref>].</p>
<p>TGM2 has a pivotal role in celiac disease pathogenesis through generating immunogenic peptides from gliadin and because of the appearance of pathologic anti-TGM2 antibodies during the course of the disease. It is interesting to see that there is practically no damaging nsSNV located in the identified celiac epitope relevant amino acid residues, namely epitope 1 which is composed of Lys30, Arg116, His134 and epitope 2 consisting of Arg19, Glu153, Glu154, Met659 [<xref ref-type="bibr" rid="pone.0172189.ref049">49</xref>, <xref ref-type="bibr" rid="pone.0172189.ref050">50</xref>].</p>
</sec>
<sec id="sec018">
<title>Occurrence of nsSNVs at intrinsically disordered regions embedding short linear motifs</title>
<p>The sequences of many proteins contain short, loosely-defined protein interaction sites that mediate recognition and targeting activities and provide wide range of functionality to proteins [<xref ref-type="bibr" rid="pone.0172189.ref051">51</xref>]. These interaction sites are called Short Linear Motifs (SLiMs) composed of low complexity short peptide regions (3–20 residues long) which mediate post-translational modifications and protein-protein interactions. Mostly SLiMs are embedded in polypeptide segments that lack well-defined tertiary structure. These unstructured regions are referred to as intrinsically disordered regions (IDRs) and they are involved in diverse functions. About 22% of human disease mutations occur in intrinsically disordered regions [<xref ref-type="bibr" rid="pone.0172189.ref051">51</xref>]. Recently we reported 13 IDRs embedding 39 SLiMs in human TGM2 [<xref ref-type="bibr" rid="pone.0172189.ref004">4</xref>] and we looked for the presence of damaging nsSNVs in these regions. The damaging nsSNVs located in IDRs embedding SLiMs are given in <xref ref-type="table" rid="pone.0172189.t002">Table 2</xref>. They target 8 IDRs embedding 27 SLiMs and most of the nsSNVs are concentrated in the IDRs 208–217, 411–414, and 428–473 located in the catalytic core domain (<xref ref-type="table" rid="pone.0172189.t002">Table 2</xref>).</p>
<table-wrap id="pone.0172189.t002" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172189.t002</object-id>
<label>Table 2</label>
<caption>
<title>Damaging nsSNVs located in ID regions embedding SLiMs in TGM2.</title>
</caption>
<alternatives>
<graphic id="pone.0172189.t002g" xlink:href="pone.0172189.t002"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="1" rowspan="1">IDR</th>
<th align="center" colspan="1" rowspan="1">Short linear motifs</th>
<th align="center" colspan="1" rowspan="1">Explanation</th>
<th align="center" colspan="1" rowspan="1">Damaging nsSNVs</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">65–74</td>
<td align="left" colspan="1" rowspan="1">• LIG_SH3_3 [59–65]</td>
<td align="left" colspan="1" rowspan="1">SH3 binding domain</td>
<td align="left" colspan="1" rowspan="1">• p.Gly64Ser</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">208–217</td>
<td align="left" colspan="1" rowspan="1">• DOC_MAPK_1 [213–220]<break></break>• DOC_WW_Pin1_4 [213–218]<break></break>• MOD_GSK3_1 [209–216]<break></break>• MOD_CK1_1 [212–218]<break></break>• MOD_PKA_2 [212–218]<break></break>• MOD_ProDKin_1 [213–219]</td>
<td align="left" colspan="1" rowspan="1">Docking interaction in MAP kinase cascade (exemplified cJun); binds WW domains, involved in proline directed phosphorylation signaling pathways; phosphorylation motifs (CK1, GSK3,PKA, proline-directed kinase)</td>
<td align="left" colspan="1" rowspan="1">• p.Arg209Cys<break></break>• p.Arg213Cys<break></break>• p.Arg214His<break></break>• p.Val218Ala<break></break>• p.Val220Met</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">358–367</td>
<td align="left" colspan="1" rowspan="1">• DOC_WW_Pin1_4 [357–362]<break></break>• LIG_FHA_2 [358–364]<break></break>• LIG_TRAF2_1 [360–363]<break></break>• LIG_TRAF6 [359–367]<break></break>• MOD_CK2_1 [357–363]<break></break>• MOD_ProDKin_1 [357–363]</td>
<td align="left" colspan="1" rowspan="1">Binds WW domains, involved in proline directed phosphorylation signaling pathways; TRAF2 and TRAF6 binding motif; CK2 and proline-directed kinase phosphorylation motif</td>
<td align="left" colspan="1" rowspan="1">• p.Thr360Met<break></break>• p.Glu366Lys</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">411–414</td>
<td align="left" colspan="1" rowspan="1">• LIG_ACTIN_WH2_2 [409–427]<break></break>• MOD_GSK3_1 [408–415]<break></break>• MOD_PLK [408–415]</td>
<td align="left" colspan="1" rowspan="1">Actin binding motif (WH2 domains); GSK3 and PLK phosphorylation site;</td>
<td align="left" colspan="1" rowspan="1">• p.Asp409Val<break></break>• p.Asp409Gly<break></break>• p.Gly410Glu<break></break>• p.Lys414Thr</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">428–473</td>
<td align="left" colspan="1" rowspan="1">• DOC_USP7_1 [446–450]<break></break>• MOD_CK1_1 [427–433]<break></break>• MOD_CK2_1 [446–452]</td>
<td align="left" colspan="1" rowspan="1">USP7 binding motif; CK1 and CK2 phosphorylation motif</td>
<td align="left" colspan="1" rowspan="1">• p.Glu447Lys<break></break>• p.Gly448Glu<break></break>• p.Val431Leu<break></break>• p.Val431Met</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">597–602</td>
<td align="left" colspan="1" rowspan="1">• TRG_LysEnd_APsAcLL_1 [599–604]<break></break>• TRG_NLS_MonoExtN_4 [597–604]<break></break>• DOC_CYCLIN_1 [601–604]<break></break>• DOC_MAPK_1 [601–609]</td>
<td align="left" colspan="1" rowspan="1">Sorting and directing signal to lysosomal endosomal compartment; NLS; cyclin recognition signal; MAPK docking motif</td>
<td align="left" colspan="1" rowspan="1">• p.Arg601Cys</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">626–647</td>
<td align="left" colspan="1" rowspan="1">• DEG_APCC_DBOX_1 [650–658]<break></break>• DOC_MAPK_1 [649–657]<break></break>• LIG_FHA_1 [633–639]</td>
<td align="left" colspan="1" rowspan="1">APCC binding destruction signal; MAPK docking motif; FHA binding motif</td>
<td align="left" colspan="1" rowspan="1">• p.Pro656Leu<break></break>• p.Thr635Met</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">685–687</td>
<td align="left" colspan="1" rowspan="1">• DOC_MAPK_1 [674–684]</td>
<td align="left" colspan="1" rowspan="1">MAPK docking motif</td>
<td align="left" colspan="1" rowspan="1">• p.Ala675Pro<break></break>• p.Val676Ala<break></break>• p.Arg680Pro<break></break>• p.Ile684Thr</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001">
<p>Column 1 indicates the position of IDRs; column 2 shows the names of SLiMs and their coordinates in square brackets; column 3 provides explanation for the function of the given SLiM; column 4 lists damaging nsSNVs in TGM2.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec019">
<title>Occurrence of nsSNVs at LC3 interacting regions</title>
<p>Autophagy was initially considered to be a nonselective process for bulk breakdown of cytosolic material. However, recent evidence points towards a selective mode of autophagy mediated by the so-called selective autophagy receptors [<xref ref-type="bibr" rid="pone.0172189.ref052">52</xref>]. Interaction between selective autophagy receptors and proteins of the autophagy-related protein 8 families are mediated by short linear sequence motifs called LIRs which ensures the targeting of autophagy receptors to LC3 or other autophagy-related protein 8 family proteins anchored in the phagophore membrane. The canonical LIR motif consists of a short tetrapeptide sequence WxxL (where x could be any residue), which interact with two distinct hydrophobic pockets of LC3 [<xref ref-type="bibr" rid="pone.0172189.ref052">52</xref>]. As TGM2 was shown to be involved in autophagy [<xref ref-type="bibr" rid="pone.0172189.ref053">53</xref>], SNVs in LIRs motifs could impact this process. LIR motifs and 11 damaging nsSNVs in TGM2 are shown in <xref ref-type="table" rid="pone.0172189.t003">Table 3</xref>. Two damaging nsSNVs target xLIR motif <sup>352</sup>EGWQAL<sup>357</sup> and WxxL motifs are targeted by nine damaging nsSNVs (<xref ref-type="table" rid="pone.0172189.t003">Table 3</xref>). Non-synonymous SNVs present within LIRs might have functional implications in autophagic process, given the role of TGM2 in autophagosome maturation [<xref ref-type="bibr" rid="pone.0172189.ref053">53</xref>] and its interaction with autophagy cargo proteins [<xref ref-type="bibr" rid="pone.0172189.ref054">54</xref>].</p>
<table-wrap id="pone.0172189.t003" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172189.t003</object-id>
<label>Table 3</label>
<caption>
<title>Damaging nsSNVs located in potential LC3 interacting regions.</title>
</caption>
<alternatives>
<graphic id="pone.0172189.t003g" xlink:href="pone.0172189.t003"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="1" rowspan="1">MOTIF</th>
<th align="center" colspan="1" rowspan="1">START</th>
<th align="center" colspan="1" rowspan="1">END</th>
<th align="center" colspan="1" rowspan="1">LIR sequence</th>
<th align="center" colspan="1" rowspan="1">TGM2 damaging nsSNV</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1">xLIR</td>
<td align="center" colspan="1" rowspan="1">352</td>
<td align="center" colspan="1" rowspan="1">357</td>
<td align="center" colspan="1" rowspan="1"><underline><bold>EG</bold></underline>WQAL</td>
<td align="left" colspan="1" rowspan="1">• p.Glu352Lys<break></break>• p.Gly353Val</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">WxxL</td>
<td align="center" colspan="1" rowspan="1">38</td>
<td align="center" colspan="1" rowspan="1">43</td>
<td align="center" colspan="1" rowspan="1">PFWLT<underline><bold>L</bold></underline></td>
<td align="left" colspan="1" rowspan="1">• p.Leu43Arg</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">WxxL</td>
<td align="center" colspan="1" rowspan="1">133</td>
<td align="center" colspan="1" rowspan="1">138</td>
<td align="center" colspan="1" rowspan="1">GHFI<underline><bold>L</bold></underline>L</td>
<td align="left" colspan="1" rowspan="1">• p.Leu137Phe</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">WxxL</td>
<td align="center" colspan="1" rowspan="1">278</td>
<td align="center" colspan="1" rowspan="1">283</td>
<td align="center" colspan="1" rowspan="1">WVFA<underline><bold>AV</bold></underline></td>
<td align="left" colspan="1" rowspan="1">• p.Ala282Thr<break></break>• p.Val283Met</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">WxxL</td>
<td align="center" colspan="1" rowspan="1">392</td>
<td align="center" colspan="1" rowspan="1">397</td>
<td align="center" colspan="1" rowspan="1">FVF<underline><bold>A</bold></underline>EV</td>
<td align="left" colspan="1" rowspan="1">• p.Ala395Val</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">WxxL</td>
<td align="center" colspan="1" rowspan="1">514</td>
<td align="center" colspan="1" rowspan="1">519</td>
<td align="center" colspan="1" rowspan="1">VSY<underline><bold>N</bold></underline>GI</td>
<td align="left" colspan="1" rowspan="1">• p.Asn517Ser</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">WxxL</td>
<td align="center" colspan="1" rowspan="1">677</td>
<td align="center" colspan="1" rowspan="1">682</td>
<td align="center" colspan="1" rowspan="1">KGF<underline><bold>R</bold></underline>NV</td>
<td align="left" colspan="1" rowspan="1">• p.Arg680Trp<break></break>• p.Arg680Pro<break></break>• p.Arg680Gln</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001">
<p>Column 1 represent the LIR and WxxL motifs, column 2 and 3 represent the start and end of each motif in TGM2, column 4 represent the sequence of LIR motifs and human TGM2 damaging nsSNVs are underlined in bold text.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="sec020">
<title>Population scale occurrence of non-synonymous SNV in TGMs</title>
<p>The influence of nsSNVs of proteins arising in the human population is significantly determined by their penetrance. The nsSNV allele counts in the population covered in the ExAC dataset are the highest for TGM3 and TGM4 (over 0.2 million) and lowest for TGM2 and TGM1 (2601 and 5174, respectively) (<xref ref-type="table" rid="pone.0172189.t004">Table 4</xref>). Common variants are typically defined as those found with &gt; 5% allele frequency and rare variants as those found with &lt; 0.5% allele frequency [<xref ref-type="bibr" rid="pone.0172189.ref055">55</xref>]. The F13a, TGM3, TGM4, TGM5, and TGM6 have common nsSNV variants, TGM1 and TGM7 nsSNV variants occur in frequencies less than 5%. The allele frequency value for the three most frequent variants in case of each family member is showed in <xref ref-type="fig" rid="pone.0172189.g002">Fig 2</xref>. All the TGM2 nsSNVs were rare with allele frequency values less than 0.5%. The TGM2 nsSNV with highest allele frequency values are p.Arg76His (0.47%), p.Val542Phe (0.38%), p.Glu366Lys (0.11%), p.Arg433Gln (0.10%) and p.Glu469Gly (0.10%); of these only p.Val542Phe has potentially damaging PolyPhen score.</p>
<fig id="pone.0172189.g002" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172189.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Allele frequencies of three most frequent non-synonymous variants in transglutaminase family genes.</title>
<p>Values were calculated based on the ExAC database. For each family, nsSNVs with top three allele frequency (%) values are shown. <bold>F13a</bold>: p.Pro565Leu (21%), p.Glu652Gln (20.8%), p.Val35Leu (20.6%); <bold>TGM1</bold>: p.Val518Met (1.04%), p.Glu520Gly (0.56%), p.Ser42Tyr (0.40%); <bold>TGM2</bold>: see in text; <bold>TGM3</bold>: p.Gly654Arg (28.7%), p.Thr13Lys (19%), p.Ser249Asn (11.2%); <bold>TGM4</bold>: p.Glu313Lys (49%), p.Val409Ile (44.7%), p.Arg372Cys (42.8%); <bold>TGM5</bold>: p.Ala352Gly (14.8%), p.Val504Met (1.4%), p.Gln521Arg (1.25%); <bold>TGM6</bold>: p.Met58Val (9.2%), p.Arg448Trp (2.80%), p.Ala141Glu (0.9%); <bold>TGM7</bold>: p.Pro564Leu (3.4%), p.Val103Leu (1.07%), p.Val515Leu (0.82%).</p>
</caption>
<graphic xlink:href="pone.0172189.g002"></graphic>
</fig>
<table-wrap id="pone.0172189.t004" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172189.t004</object-id>
<label>Table 4</label>
<caption>
<title>Summary of population frequencies of nsSNVs alleles of transglutaminases in the ExAC database covering 60,706 individuals.</title>
</caption>
<alternatives>
<graphic id="pone.0172189.t004g" xlink:href="pone.0172189.t004"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center" colspan="1" rowspan="1">Genes</th>
<th align="center" colspan="1" rowspan="1">Total number of nsSNV types</th>
<th align="center" colspan="1" rowspan="1">Allele count</th>
<th align="center" colspan="1" rowspan="1">Number associated with homozygotes</th>
<th align="center" colspan="1" rowspan="1">Number of homozygote individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1">F13a</td>
<td align="center" colspan="1" rowspan="1">283</td>
<td align="center" colspan="1" rowspan="1">88654</td>
<td align="center" colspan="1" rowspan="1">9</td>
<td align="center" colspan="1" rowspan="1">9214</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM1</td>
<td align="center" colspan="1" rowspan="1">320</td>
<td align="center" colspan="1" rowspan="1">5174</td>
<td align="center" colspan="1" rowspan="1">13</td>
<td align="center" colspan="1" rowspan="1">25</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM2</td>
<td align="center" colspan="1" rowspan="1">272</td>
<td align="center" colspan="1" rowspan="1">2601</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="center" colspan="1" rowspan="1">12</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM3</td>
<td align="center" colspan="1" rowspan="1">313</td>
<td align="center" colspan="1" rowspan="1">205153</td>
<td align="center" colspan="1" rowspan="1">12</td>
<td align="center" colspan="1" rowspan="1">73495</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM4</td>
<td align="center" colspan="1" rowspan="1">279</td>
<td align="center" colspan="1" rowspan="1">265931</td>
<td align="center" colspan="1" rowspan="1">17</td>
<td align="center" colspan="1" rowspan="1">66931</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM5</td>
<td align="center" colspan="1" rowspan="1">273</td>
<td align="center" colspan="1" rowspan="1">27038</td>
<td align="center" colspan="1" rowspan="1">12</td>
<td align="center" colspan="1" rowspan="1">2206</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM6</td>
<td align="center" colspan="1" rowspan="1">336</td>
<td align="center" colspan="1" rowspan="1">111028</td>
<td align="center" colspan="1" rowspan="1">23</td>
<td align="center" colspan="1" rowspan="1">47462</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">TGM7</td>
<td align="center" colspan="1" rowspan="1">293</td>
<td align="center" colspan="1" rowspan="1">11585</td>
<td align="center" colspan="1" rowspan="1">13</td>
<td align="center" colspan="1" rowspan="1">170</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001">
<p>Column 2 shows the total number of nsSNVs; column 3 has the observed allele counts for the nsSNVs; column 4 presents the number of nsSNVs associated with homozygotes; column 5 contains the number of homozygote individuals</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec021">
<title>Homozygous occurrence of TGM2 non-synonymous SNVs</title>
<p>Since damaging TGM2 nsSNVs occur at some functional sites of the protein we have decided to screen databases to see whether homozygous occurrence of nsSNVs is tolerated by individuals as compared to nsSNV variants of the other transglutaminase family members. Furthermore, we wanted to learn how the protein products of TGM2 nsSNVs alleles found in homozygotes function in biochemical tests.</p>
<p>The current ExAC dataset contains the revealed existing homozygous nsSNVs for transglutaminase family members (<xref ref-type="table" rid="pone.0172189.t004">Table 4</xref>). TGM3, TGM4, and TGM6 have the highest (in the range of 47 to 73 thousands), while TGM2, TGM1, and TGM7 have the lowest (12, 25, and 170 respectively) numbers of such homozygous occurrences (<xref ref-type="table" rid="pone.0172189.t004">Table 4</xref>). The number of nsSNV alleles associated with the homozygotes is lowest for TGM2 and F13a. There are only six TGM2 nsSNVs which occur all together in 12 individuals in homozygous form in various populations in the World, by far the lowest number in the TGM family (<xref ref-type="table" rid="pone.0172189.t005">Table 5</xref>). Amidst these, three nsSNVs have probably damaging PolyPhen scores (p.Arg222Gln, p.Val542Phe and p.Pro612Thr), p.Pro612Thr is destabilizing in both closed and opened conformations, whereas p.Val542Phe and p.Asp671Asn mostly affect the closed conformation (<xref ref-type="table" rid="pone.0172189.t005">Table 5</xref>).</p>
<table-wrap id="pone.0172189.t005" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172189.t005</object-id>
<label>Table 5</label>
<caption>
<title>The 12 human TGM2 homozygotes related to 6 nsSNVs.</title>
</caption>
<alternatives>
<graphic id="pone.0172189.t005g" xlink:href="pone.0172189.t005"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
<col align="left" span="1" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="2">Position and Change</th>
<th align="left" colspan="1" rowspan="2">Allele Frequency [%]</th>
<th align="left" colspan="1" rowspan="2">Domains</th>
<th align="left" colspan="2" rowspan="1">Stability ΔΔG [kcal/mol]</th>
<th align="left" colspan="1" rowspan="2">PolyPhen/ SIFT</th>
<th align="left" colspan="1" rowspan="2">Number of Homozygote Individuals</th>
<th align="left" colspan="1" rowspan="2">Population</th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="1">Closed Form</th>
<th align="center" colspan="1" rowspan="1">Open Form</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">R76H</td>
<td align="left" colspan="1" rowspan="1">0.47</td>
<td align="left" colspan="1" rowspan="1">β-sandwich</td>
<td align="left" colspan="1" rowspan="1">0</td>
<td align="left" colspan="1" rowspan="1">0.57</td>
<td align="left" colspan="1" rowspan="1">Benign</td>
<td align="left" colspan="1" rowspan="1">5</td>
<td align="left" colspan="1" rowspan="1">• 2 East Asian<break></break>• 3 Latino</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">R222Q</td>
<td align="left" colspan="1" rowspan="1">0.048</td>
<td align="left" colspan="1" rowspan="1">Catalytic</td>
<td align="left" colspan="1" rowspan="1">-0.98</td>
<td align="left" colspan="1" rowspan="1">0.71</td>
<td align="left" colspan="1" rowspan="1">Probably damaging</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">• South Asian</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">R433Q</td>
<td align="left" colspan="1" rowspan="1">0.10</td>
<td align="left" colspan="1" rowspan="1">Catalytic</td>
<td align="left" colspan="1" rowspan="1">0.67</td>
<td align="left" colspan="1" rowspan="1">0.51</td>
<td align="left" colspan="1" rowspan="1">Benign</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">• South Asian</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">V542F</td>
<td align="left" colspan="1" rowspan="1">0.38</td>
<td align="left" colspan="1" rowspan="1">β-barrel 1</td>
<td align="left" colspan="1" rowspan="1">2.29</td>
<td align="left" colspan="1" rowspan="1">-1.11</td>
<td align="left" colspan="1" rowspan="1">Probably damaging</td>
<td align="left" colspan="1" rowspan="1">3</td>
<td align="left" colspan="1" rowspan="1">• 2 East Asian<break></break>• 1 African</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">P612T</td>
<td align="left" colspan="1" rowspan="1">0.018</td>
<td align="left" colspan="1" rowspan="1">β-barrel 2</td>
<td align="left" colspan="1" rowspan="1">2.26</td>
<td align="left" colspan="1" rowspan="1">3.83</td>
<td align="left" colspan="1" rowspan="1">Probably damaging</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">• South Asian</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">D671N</td>
<td align="left" colspan="1" rowspan="1">0.013</td>
<td align="left" colspan="1" rowspan="1">β-barrel 2</td>
<td align="left" colspan="1" rowspan="1">1.17</td>
<td align="left" colspan="1" rowspan="1">0.10</td>
<td align="left" colspan="1" rowspan="1">Benign</td>
<td align="left" colspan="1" rowspan="1">1</td>
<td align="left" colspan="1" rowspan="1">• African</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t005fn001">
<p>Column 1 homozygous nsSNVs in TGM2; column 2 allele frequency of the given nsSNV; column 3 shows domain location in TGM2; column 4, 5 stability values in closed and opened conformation; column 6 PolyPhen/SIFT scores; column 7 presents number of homozygote individuals for each nsSNV and column 8 indicates population distribution of the 12 homozygote individuals. The dbSNP identifiers of the TGM2 homozygous nonsynonymous variants: p.Arg76His (rs41274720), p.Arg222Gln (rs200551434), p.Arg433Gln (rs142184177), p.Val542Phe (rs115436227), p.Pro612Thr (rs199563008), p.Asp671Asn (rs141236503).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec022">
<title>Biochemical analysis of homozygous non synonymous TGM2 variants</title>
<p>Since homozygous nsSNVs can be associated with various diseases we analyzed the functional impact of TGM2 homozygous nsSNVs. We produced all the six homozygous occurring TGM2 variants containing the respective nsSNVs by site directed mutagenesis and tested them in biochemical assays. We measured transglutaminase activity of the variants using two previously published kinetic assays [<xref ref-type="bibr" rid="pone.0172189.ref017">17</xref>, <xref ref-type="bibr" rid="pone.0172189.ref056">56</xref>]. Except p.Arg222Gln, the transamidase activity of variants is comparable in the two assays. p.Arg222Gln was completely active in amine incorporation assay but inactive in the protein crosslinking assay (<xref ref-type="fig" rid="pone.0172189.g003">Fig 3</xref>). The variant p.Arg76His showed increase in transamidase activity compared to the wild type enzyme and variant p.Val542Phe showed 40% less activity than wild type TGM2 in both assays. Compared to the wild type, p.Pro612Thr variant showed 40% less activity in the amine incorporation assay but only 18% less activity in the protein crosslinking assay. Interestingly both p.Val542Phe and p.Pro612Thr variants have predicted damaging PolyPhen/SIFT scores (<xref ref-type="table" rid="pone.0172189.t005">Table 5</xref>). Calcium dependence of the transamidase reaction was also measured based on the amine incorporation assay (<xref ref-type="fig" rid="pone.0172189.g003">Fig 3</xref>). Variant p.Arg76His exhibited high transamidase activity and variants p.Val542Phe, p.Pro612Thr had less activity than wild type at both measured Ca<sup>2+</sup> concentrations (<xref ref-type="fig" rid="pone.0172189.g003">Fig 3</xref>). Variants p.Arg433Gln, p.Asp671Asn manifested a several fold increase in transamidase activity compared with wild type at 0.25 mM Ca<sup>2+</sup> concentration. Variant p.Arg222Gln showed the lowest efficiency at 0.25 mM calcium concentration, increasing of which restored activity. It is known that Ca<sup>2+</sup> and nucleotides reciprocally regulate transglutaminase reactions. The nucleotide binding of the variants were examined using an analog, BODIPY FL GTPγS. At 250 nM enzyme concentration, 18% higher GTP binding was observed for p.Arg76His and p.Asp671Asn than wild type and 24% lower GTP binding in case of p.Pro612Thr (<xref ref-type="fig" rid="pone.0172189.g003">Fig 3</xref>).</p>
<fig id="pone.0172189.g003" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172189.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Biochemical characterization of the six homozygous nsSNVs of TGM2.</title>
<p>Kinetic characterization of the transamidase activity of TGM2 variants and wild type at 3 mM CaCl<sub>2</sub> concentration using amine incorporation assay [<xref ref-type="bibr" rid="pone.0172189.ref056">56</xref>] and protein crosslinking assay [<xref ref-type="bibr" rid="pone.0172189.ref017">17</xref>]. Calcium dependence of kinetic transamidase reaction with 0.25 and 1 mM calcium concentrations using amine incorporation assay. Comparison of the kinetic isopeptidase activity of TGM2 variants at 5 mM CaCl<sub>2</sub> concentration using Zedira assay and crosslinked protein substrate [<xref ref-type="bibr" rid="pone.0172189.ref018">18</xref>]. The relative activities are calculated as a percentage of the activity values of the wild type TGM2. Comparison of BODIPY FL GTPγS binding of variants and wild type TGM2 proteins with different concentrations of TGM2 (50 and 250 nM). The change in the fluorescence intensity (Ex/Em: 485/520 nm) was determined after 15 minutes of incubation. Binding is shown as a percentage of maximum binding in case of wild type TGM2 [<xref ref-type="bibr" rid="pone.0172189.ref029">29</xref>]. The Fibronectin binding property of the TGM2 variants was tested using a previously published direct ELISA assay [<xref ref-type="bibr" rid="pone.0172189.ref016">16</xref>]. Data are presented as means with ± standard deviations from three separate experiments done in triplicate. All the data were analyzed by GraphPad Prism 7.</p>
</caption>
<graphic xlink:href="pone.0172189.g003"></graphic>
</fig>
<p>TGM2 also possess isopeptidase activity when previously formed isopeptide bonds are cleaved. The isopeptidase activity of the six variants was also compared using a commercially available small chemically produced substrate and a recently published protein based real-time kinetic method [<xref ref-type="bibr" rid="pone.0172189.ref018">18</xref>]. The p.Arg222Gln variant is only 15% active in the commercial Zedira assay and completely inactive in the protein based method (<xref ref-type="fig" rid="pone.0172189.g003">Fig 3</xref>). Compared to wild type, the variants p.Val542Phe and p.Pro612Thr showed less isopeptidase activity in the Zedira assay but normal activity in the protein based method. While variants p.Arg76His, p.Asp671Asn showed increase in activity compared to the wild type in both the assays. Since interaction of TGM2 with fibronectin has a crucial role in scaffolding processes in the extracellular matrix of the cells, the fibronectin-binding property of the variants was tested by an ELISA method. The variants p.Val542Phe, p.Pro612Thr showed 15% less fibronectin binding but other variants bound fibronectin similarly to the wild type enzyme (<xref ref-type="fig" rid="pone.0172189.g003">Fig 3</xref>).</p>
<p>Homozygous variants p.Arg76His and p.Asp671Asn with high transamidase, isopeptidase activities and GTP binding ability do not coincide with any of the functional sites, predicted IDRs, novel clusters and have benign or tolerated scores. The p.Arg433Gln variant with almost normal activity compared to wild type is part of the Ca<sup>2+</sup> binding site S5 (432–440) and IDR (428–473) embedding SLiMs like USP7 binding motif, TRAF2 binding motif, and CK1 and CK2 phosphorylation motif. A PolyPhen damaging variant with decreased activity is p.Val542Phe located within the MOD CK1 phosphorylation site and MOD PLK site phosphorylated by polo like kinases. Another potentially damaging variant p.Pro612Thr with less transamidase, isopeptidase and GTP binding is near to an IDR (597–602) and a novel amino acid cluster PVA (613–615) [<xref ref-type="bibr" rid="pone.0172189.ref030">30</xref>]. The homozygous variant p.Asp671Asn is located in the C-terminal class 3 PDZ-binding motif.</p>
<p>The PolyPhen damaging variant p.Arg222Gln, located to the catalytic core domain near Ca<sup>2+</sup> binding site S1 (226–233) and the SLiM, STAT5 Src Homology 2 (SH2) domain binding motif, has very low transamidase activity at physiological Ca<sup>2+</sup> concentration. Moreover, the isopeptidase activity of this variant is completely lost. To assess the effect of the p.Arg222Gln allele on the structure we compared the situations where of the calcium binding sites none, only site 1, or all three are occupied by metal using the existing crystal structures and newly built homology models of TGM2 (<xref ref-type="fig" rid="pone.0172189.g004">Fig 4</xref>). We attribute the observed behavior of the Q222 variant to a disrupted H-bond network that leads to altered conformation of the loop, P359-G372, and consequently to reduced calcium affinities at site 1 and 2, and to a topology which disfavors proper interaction with a protein amine donor. Taken together, biochemical data demonstrates that only one of the very rarely occurring homozygous nsSNVs containing variant of TGM2 lead to significant decrease of one of its basic functional properties.</p>
<fig id="pone.0172189.g004" orientation="portrait" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0172189.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Structural interpretation of the effect of the p.Arg222Gln variation on enzyme activity.</title>
<p>We analyzed the interactions of R222 in a homology model of TGM2 containing three bound calcium ions (pink spheres), which supposedly corresponds to the active form (cyan: N-terminal, grey: catalytic, green and red: first and second beta barrel domains respectively). The squared area in the left panel is magnified on the right. R222 is located in the middle of the solvent accessible surface of the α-helix leading up to calcium binding site S1 (226–233). R222 is at the core of an H-bond network (light blue dashed lines) that serves to bundle neighboring structural elements of TGM2 together. Upon binding of calcium to site 1, H-bonds between E232, N229 and backbone atoms of Y369, and H-bonds of R222 to S365, E366, G372, and D389 cooperatively tether the flexible loop, P359-G372. The changing conformation of this loop leads to reorganization of another non-covalent interaction network near calcium binding site 2, including a directly calcium binding residue, N306, for metal binding, and to honing of the charge relay duad, E305-E363 that has recently identified importance for catalysis [<xref ref-type="bibr" rid="pone.0172189.ref026">26</xref>]. The Q222 variant (wheat) fails to establish the critical H-bonds with S365, E366, and E389, thus the calcium binding of both sites are impaired and the charge relay system is also negatively affected. The same loop, most probably, also contributes residues to the amine substrate binding surface and controls access to the active site (C277/H335/D358), likely explaining that the Q222 enzyme has conserved transamidase activity for a small molecular amine, but compromised cross-linking activity towards a protein amine donor and lost isopeptidase activity for a protein-peptide conjugate.</p>
</caption>
<graphic xlink:href="pone.0172189.g004"></graphic>
</fig>
</sec>
<sec id="sec023">
<title>Heterozygous and homozygous LOF variants of TGMs</title>
<p>The very rare generation of damaging nsSNVs alleles of TGM2 in humans and the observation that even the so far found homozygous TGM2 nsSNVs keep their basic biochemical properties (with one exception with decreased activities), prompted us to check the population frequency of its LOF variants compared to the other genes. Disease causing TGM2 LOF variants have not been reported so far in humans. Neither TGM2 nor the other TGMs are among the 3230 genes of the ExAC database which are unable to function normally after loss of one copy of the gene, even if the other copy is intact (haploinsufficiency) [<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>]. In general, large-scale sequencing projects revealed a surprisingly large number of LOF variants and fully knocked out (homozygous or compound heterozygous) genes in genomes of healthy individuals [<xref ref-type="bibr" rid="pone.0172189.ref057">57</xref>]. We compiled the LOF variants of transglutaminase family members from different populations with available data (<xref ref-type="supplementary-material" rid="pone.0172189.s002">S2 Table</xref>). Heterozygous LOF variants for all the transglutaminases were identified in the dataset of the Atherosclerosis Risk in Communities (ARIC) cohort study (<xref ref-type="supplementary-material" rid="pone.0172189.s002">S2 Table</xref>) [<xref ref-type="bibr" rid="pone.0172189.ref058">58</xref>]. In the ExAC dataset (where full knock outs can be found), LOF heterozygotes were identified for all the members of the family but in homozygous form only for TGM4 and TGM6 [<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>]. Transglutaminase LOF variants with highest allele frequency values were observed for TGM4 (0.83%) and F13a (0.24%) while the LOF (MAF) values were very low for the others: TGM1 (0.03%), TGM2 (0.015%), TGM3 (0.003%), TGM5 (0.006%), TGM6 (0.04%), TGM7 (0.017%). Exon sequencing data from 185 individuals as part of the pilot phase of the 1000 Genomes Project was analyzed and 2951 LOF variants, rare and likely deleterious LOF alleles (including 26 known and 21 predicted severe disease-causing variants) were reported [<xref ref-type="bibr" rid="pone.0172189.ref057">57</xref>]; this dataset contains a homozygous TGM6 LOF variant. A list of autosomal genes that are completely knocked out in the Icelandic bottlenecked population by rare LOF mutations have been published [<xref ref-type="bibr" rid="pone.0172189.ref010">10</xref>]; these data show that 7.7% (1171) of protein coding genes are completely knocked out by loss-of-function variants including TGM1, TGM4, and TGM5 (<xref ref-type="supplementary-material" rid="pone.0172189.s002">S2 Table</xref>). Recently, 3222 exomes of British adults of Pakistani heritage, a consanguineous population, was sequenced and 1111 rare gene knockouts in 781 genes were identified finding one homozygous TGM4 LOF variant [<xref ref-type="bibr" rid="pone.0172189.ref012">12</xref>]. A homozygous TGM4 LOF variant was also identified in the Simons Simplex Collection (SSC) dataset, a project aimed to improve the understanding and research of autism spectrum disorders [<xref ref-type="bibr" rid="pone.0172189.ref059">59</xref>]. TGM2, TGM3, and TGM7 LOF variants in homozygous or compound heterozygous form have not been identified in any of these datasets.</p>
</sec>
<sec id="sec024">
<title>Summary of transglutaminase mutations listed in OMIM database</title>
<p>Allelic variations responsible for human inherited diseases are listed in the Online Mendelian Inheritance in Man (OMIM) database, an Online Catalog of human genes and genetic disorders. We collected OMIM data for transglutaminase family which is shown in <xref ref-type="supplementary-material" rid="pone.0172189.s003">S3 Table</xref>. F13a autosomal recessive mutations lead to F13a deficiency [<xref ref-type="bibr" rid="pone.0172189.ref060">60</xref>, <xref ref-type="bibr" rid="pone.0172189.ref061">61</xref>, <xref ref-type="bibr" rid="pone.0172189.ref062">62</xref>], TGM1 has disease causing mutations in autosomal recessive congenital ichthyosis [<xref ref-type="bibr" rid="pone.0172189.ref063">63</xref>, <xref ref-type="bibr" rid="pone.0172189.ref064">64</xref>], TGM5 homozygous LOF mutations cause acral peeling skin syndrome [<xref ref-type="bibr" rid="pone.0172189.ref065">65</xref>, <xref ref-type="bibr" rid="pone.0172189.ref066">66</xref>, <xref ref-type="bibr" rid="pone.0172189.ref067">67</xref>] and TGM6 mutations are associated with spinocerebellar ataxia 35 [<xref ref-type="bibr" rid="pone.0172189.ref068">68</xref>]. Data have not been found for inherited disease related to TGM2, TGM3, TGM4, and TGM7 mutations.</p>
</sec>
</sec>
<sec id="sec025" sec-type="conclusions">
<title>Discussion</title>
<p>Large scale exome sequencing has opened a new avenue to study molecular background of polymorphism and to understand unsolved Mendelian and non-Mendelian genetic disorders [<xref ref-type="bibr" rid="pone.0172189.ref007">7</xref>, <xref ref-type="bibr" rid="pone.0172189.ref069">69</xref>, <xref ref-type="bibr" rid="pone.0172189.ref070">70</xref>, <xref ref-type="bibr" rid="pone.0172189.ref071">71</xref>]. Our survey reveals that human transglutaminase genes harbor about the same number of nsSNV types in accord with the assumed generational mutation rate of ~1–1.5 × 10<sup>−8</sup> for single-base substitutions, but differ very much in their response to purifying selection. Deleterious variants are expected to have lower allele frequencies than neutral ones, due to negative selection. Genomic changes in F13a, TGM3, TGM4, and TGM6 are most tolerated with highest nsSNV allele frequency values, allele number and homozygote individuals but are least tolerated in TGM1, TGM7 and particularly TGM2 with low population frequencies. Evolutionary constraints are also indicated by mis_z and GDI scores for TGM1 and TGM2 in the human population. These differences are even more intriguing knowing that TGM6, TGM3 and TGM2 are located close to one another on chromosome 20q11-12. We presume that based on population frequencies and other predicted values, human TGM2 must be under high selective pressure not allowing generation of even heterozygous common variants. The similarly high evolutionary constraint on human TGM7 is a surprising finding and may initiate further studies, especially to learn the physiological function of TGM7 about which there is no available information.</p>
<p>Rare, deleterious non-synonymous variants can be lethal and are also connected to human diseases [<xref ref-type="bibr" rid="pone.0172189.ref072">72</xref>]. Caution should be taken while addressing damaging variants as some previously identified disease-causing variants were actually benign occurring at high frequencies [<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>]. Recent studies have disclosed rare, homozygous LOF variants or knockouts in genomes of healthy individuals [<xref ref-type="bibr" rid="pone.0172189.ref057">57</xref>]. So far, 1717 genes have been reported to be implicated in various Mendelian recessive disorders (the most common is cystic fibrosis) [<xref ref-type="bibr" rid="pone.0172189.ref073">73</xref>–<xref ref-type="bibr" rid="pone.0172189.ref076">76</xref>]; the lack of most of these genes is compatible with life albeit with the consequence of disease phenotypes. Based on available datasets, F13a, TGM1-TGM7 have LOF variants in heterozygote state but homozygous LOF variants have been seen only for TGM1, TGM4, TGM5, and TGM6. From classical clinical and genetic studies it has been known that humans with knock out, homozygous LOF transglutaminase genes with disease phenotype in the case of F13a (bleeding disorder, prevalence 1 in 2 millions) [<xref ref-type="bibr" rid="pone.0172189.ref060">60</xref>, <xref ref-type="bibr" rid="pone.0172189.ref061">61</xref>, <xref ref-type="bibr" rid="pone.0172189.ref062">62</xref>, <xref ref-type="bibr" rid="pone.0172189.ref077">77</xref>, <xref ref-type="bibr" rid="pone.0172189.ref078">78</xref>], TGM1 (lamellar ichthyosis, prevalence 1 in 150 thousands) [<xref ref-type="bibr" rid="pone.0172189.ref063">63</xref>, <xref ref-type="bibr" rid="pone.0172189.ref064">64</xref>], and TGM5 (acral peeling skin, prevalence &lt;1 in 1 million) [<xref ref-type="bibr" rid="pone.0172189.ref065">65</xref>, <xref ref-type="bibr" rid="pone.0172189.ref066">66</xref>, <xref ref-type="bibr" rid="pone.0172189.ref067">67</xref>] deficiencies. It is important to note that TGM2, TGM3, and TGM7 nsSNVs do not seem to be associated with any pathological phenotype except perhaps TGM2 heterozygous mutations associated with early-onset type 2 diabetes, an observation which has not been confirmed in animal experiments and large clinical cohorts [<xref ref-type="bibr" rid="pone.0172189.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0172189.ref047">47</xref>, <xref ref-type="bibr" rid="pone.0172189.ref048">48</xref>, <xref ref-type="bibr" rid="pone.0172189.ref079">79</xref>]. The most plausible explanation of this remarkable purifying selection, at least for TGM2, is its multifunctional nature. TGM2 is able to catalyze transamidation, esterification, GTPase, protein disulphide isomerase, and hydrolysis reactions [<xref ref-type="bibr" rid="pone.0172189.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0172189.ref002">2</xref>], and interacts with a large number of ligands and proteins in almost all compartments and outside of cells (reviewed in [<xref ref-type="bibr" rid="pone.0172189.ref004">4</xref>, <xref ref-type="bibr" rid="pone.0172189.ref005">5</xref>]). It is likely that almost all amino acids in the sequence have structural and functional importance and loss of any of them manifested in homozygotes would lead to deleterious consequences–even preventing full embryonic development. This conclusion and the fact that TGM2 knock-out mice are viable and are fertile raise the possibility that when compared to rodents, human TGM2 (and possibly also TGM3, TGM7) gained vital functions which have not been fully revealed, yet.</p>
<p>Information from literature unveil that disease causing SNVs are concentrated at the core of a protein [<xref ref-type="bibr" rid="pone.0172189.ref080">80</xref>]. Our study also shows that most of the TGM2 damaging nsSNVs are concentrated to the catalytic core domain. The core of the protein is hydrophobic in nature, so mutation of a hydrophobic residue to a charged or polar residue could destabilize the protein. Our stability analysis revealed that most of the highly destabilizing damaging nsSNVs are in the catalytic core domain. TGM2 nsSNVs in homozygous state so far found in humans and tested by us resulted in minor changes in biochemical activities but there were no deleterious consequences in basic structural and functional features. Only the p.Arg222Gln variant had reduced transamidase and isopeptidase activities in assays where the amine donor was a protein (S100A4). This variant also showed diminished responsiveness in the amine incorporation assay to a low but physiologically relevant range of Ca<sup>2+</sup> concentration. We attribute this to the importance of the non-covalent interaction network around R222 in positioning the loop, P359-G372. This loop carries residues, which are engaged in calcium binding at site 1 as well as substrate interactions. Without stabilizing interactions with site 1 and 2 and R222 most of this loop is intrinsically disordered and highly dynamic. The disrupted H-bond network in the Q222 variant leads to altered conformation of the loop and in consequence, probably, to reduced Ca<sup>2+</sup> affinities at sites 1 and 2, and to a topology which disfavors proper interaction with the protein amine donor.</p>
<p>None of the homozygous nsSNVs are located in conserved or unique novel functionally important sites of TGM2 which are not affected by other damaging nsSNVs either. The first cloned human recombinant TGM2 has glycine at position 224 [<xref ref-type="bibr" rid="pone.0172189.ref081">81</xref>] opposed to valine in the endogenous sequence present in the available genomic databases. We reported that the V224 variant of the enzyme has higher calcium-binding affinity, transamidation activity and isopeptidase activity [<xref ref-type="bibr" rid="pone.0172189.ref082">82</xref>] and it is important to note that there has been no nsSNV detected in the human population so far at this conserved Val224 residue either.</p>
<p>IDRs and SLiMs play a vital role in protein function, they provide conformational flexibility and facilitate diverse post-translational modifications and protein-protein interactions [<xref ref-type="bibr" rid="pone.0172189.ref083">83</xref>]. Recent studies have shown that disease-related mutations [<xref ref-type="bibr" rid="pone.0172189.ref084">84</xref>] and nsSNVs [<xref ref-type="bibr" rid="pone.0172189.ref085">85</xref>] are enriched in SLiMs in IDRs and they occur more frequently at functionally important residues of SLiMs [<xref ref-type="bibr" rid="pone.0172189.ref085">85</xref>]. Our study could reveal TGM2 damaging nsSNVs within IDRs embedding SLiMs (<xref ref-type="table" rid="pone.0172189.t002">Table 2</xref>) suggesting that sequence variability at these sites may have functional significance, although almost all of these nsSNVs occur as heterozygous alleles. A damaging nsSNV in the β-sandwich domain affects the IDR 65–74 and a SLiM motif recognized by SH3 domains. In the catalytic core, series of six nsSNVs are located in IDR 208–217 and the SLiM motifs involved in proline directed phosphorylation signaling pathways. Moreover, IDR 428–473 with SLiM USP7, which acts as a deubiquitination enzyme has four nsSNVs and IDRs 597–602, and 626–647 embedding series of SLiMs in the β-barrel 2 domain has three nsSNVs. There are several other nsSNVs that overlap with IDR-associated SLiMs (<xref ref-type="table" rid="pone.0172189.t002">Table 2</xref>), which might interfere with protein interactions and have possible functional consequences. Presence of heterozygous damaging nsSNVs within the LIR motifs of TGM2 may be also interesting to study since TGM2 is reported to play a role in autophagosome maturation [<xref ref-type="bibr" rid="pone.0172189.ref053">53</xref>] and it also interacts with autophagy cargo protein p62 to remove the ubiquitinated proteins [<xref ref-type="bibr" rid="pone.0172189.ref054">54</xref>].</p>
<p>Recent studies have identified core genes (~10% of the ~20,000 genes) essential for life in human cells in a context dependent manner [<xref ref-type="bibr" rid="pone.0172189.ref013">13</xref>, <xref ref-type="bibr" rid="pone.0172189.ref014">14</xref>, <xref ref-type="bibr" rid="pone.0172189.ref015">15</xref>]. These genes are highly conserved, do not duplicate during evolution, code for abundant proteins with multiple interactions in cells and show less than average polymorphism and deleterious mutations indicating strong purifying selection. Based on similar features one may consider TGM2 (and perhaps TGM7) also as an essential gene in humans; it is highly abundant in some cells (e.g. endothelial and smooth muscle cells) [<xref ref-type="bibr" rid="pone.0172189.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0172189.ref005">5</xref>], has broad interaction potential [<xref ref-type="bibr" rid="pone.0172189.ref004">4</xref>] and as shown above displays low polymorphism in the population scale. However, none of the transglutaminases are listed [<xref ref-type="bibr" rid="pone.0172189.ref013">13</xref>, <xref ref-type="bibr" rid="pone.0172189.ref014">14</xref>, <xref ref-type="bibr" rid="pone.0172189.ref015">15</xref>] as essential for at least proliferation and maintaining of immortalized human cell lines in culture. Much more population genomic data need to be generated and analyzed to decide whether there are TGM2 functions which are essential for the existence of the whole organism as implied by the data discussed here. It is still possible that disease causing very rare TGM2 variants will be found as full genome or exon sequencing becomes even more widely accessible. Studying these cases and continuation of systematic biochemical and <italic>in vivo</italic> investigations will be needed to answer the question what TGM2 functions reported and proposed so far are critical for human physiology.</p>
</sec>
<sec id="sec026" sec-type="supplementary-material">
<title>Supporting information</title>
<supplementary-material content-type="local-data" id="pone.0172189.s001">
<label>S1 Table</label>
<caption>
<title>Sequence and structure based predictions for single mutant human TGM2 proteins.</title>
<p>Predicted probabilities of helices (H), extended strands (E), and coils (C) are displayed (%). Predicted secondary structure for wild-type is given in column 5 and for mutations in column 9. The stability values calculated for the opened and closed forms are shown in column 11 and 12. *Residue not present in the PDB file in closed form. Out of all studied damaging nsSNVs, only 8 nsSNVs mentioned in this table had minor effects on secondary structure and others did not influence the secondary structure.</p>
<p>(PDF)</p>
</caption>
<media xlink:href="pone.0172189.s001.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0172189.s002">
<label>S2 Table</label>
<caption>
<title>Transglutaminase heterozygous and homozygous LOF types from literature.</title>
<p>Column 1 Transglutaminase genes; other columns represent different populations with number of homozygote individuals given in brackets except for column 5 (ARIC dataset) were heterozygote individuals are mentioned in brackets and 1 homozygote individual for TGM4. In case of ExAC dataset (column 6) only TGM4 and TGM6 had homozygote individuals and as there are no exact data available about heterozygote individuals, allele count is shown. Column 2 indicates Icelandic population study involving 104,220 individuals [<xref ref-type="bibr" rid="pone.0172189.ref010">10</xref>]; column 3 indicates study involving 3222 British-Pakistani-heritage adult individuals living in the UK [<xref ref-type="bibr" rid="pone.0172189.ref012">12</xref>]; column 4 denotes data from study involving 6970 individuals: (1496 cases and 5474 controls) sequenced to characterize rare complete knockouts in Autism spectrum disorders cases [<xref ref-type="bibr" rid="pone.0172189.ref059">59</xref>]; column 5 denotes data from study involving Atherosclerosis Risk in Communities [<xref ref-type="bibr" rid="pone.0172189.ref058">58</xref>]; and column 6 from ExAC datasets showing the allele count for F13a, TGM1-TGM7 and homozygote individuals for TGM4 and TGM6 [<xref ref-type="bibr" rid="pone.0172189.ref011">11</xref>].</p>
<p>(PDF)</p>
</caption>
<media xlink:href="pone.0172189.s002.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
<supplementary-material content-type="local-data" id="pone.0172189.s003">
<label>S3 Table</label>
<caption>
<title>Transglutaminase mutations in OMIM database.</title>
<p>The OMIM database was accessed on July 2016. Mutations are cataloged in OMIM in the allelic variants section of gene entries. Only selected examples listed in OMIM database is shown here. If a particular variant is present in homozygotes then it is mentioned in brackets. Full list of transglutaminase related references, are available in OMIM database.</p>
<p>(PDF)</p>
</caption>
<media xlink:href="pone.0172189.s003.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>The authors would like to thank the Exome Aggregation Consortium and the groups that provided exome variant data for comparison. A full list of contributing groups can be found at <ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/about">http://exac.broadinstitute.org/about</ext-link>. The authors are grateful to Dr. Zoltán Balajthy for critically reading the manuscript.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0172189.ref001">
<label>1</label>
<mixed-citation publication-type="journal"><name><surname>Fesus</surname><given-names>L</given-names></name>, <name><surname>Piacentini</surname><given-names>M</given-names></name>. <article-title>Transglutaminase 2: an enigmatic enzyme with diverse functions</article-title>. <source/>Trends Biochem Sci. <year>2002</year>;<volume>27</volume>: <fpage>534</fpage>–<lpage>539</lpage>. <pub-id pub-id-type="pmid">12368090</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref002">
<label>2</label>
<mixed-citation publication-type="journal"><name><surname>Lorand</surname><given-names>L</given-names></name>, <name><surname>Graham</surname><given-names>RM</given-names></name>. <article-title>Transglutaminases: crosslinking enzymes with pleiotropic functions</article-title>. <source/>Nature Reviews Molecular Cell Biology. <year>2003</year>;<volume>4</volume>: <fpage>140</fpage>–<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1038/nrm1014</pub-id>
<pub-id pub-id-type="pmid">12563291</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref003">
<label>3</label>
<mixed-citation publication-type="book"><name><surname>Demény</surname><given-names>MA</given-names></name>, <name><surname>Korponay-Szabó</surname><given-names>I</given-names></name>, <name><surname>Fésüs</surname><given-names>L</given-names></name>. <chapter-title>Structure of transglutaminases: unique features serve diverse functions</chapter-title> In: <name><surname>Hitomi</surname><given-names>K</given-names></name>, <name><surname>Kojima</surname><given-names>S</given-names></name> and <name><surname>Fesus</surname><given-names>L</given-names></name>, editors. <source/>Transglutaminases. Multiple functional modifiers and targets for new drug discovery. <publisher-name>Springer</publisher-name>; <year>2015</year> pp. <fpage>1</fpage>–<lpage>45</lpage>.</mixed-citation>
</ref>
<ref id="pone.0172189.ref004">
<label>4</label>
<mixed-citation publication-type="journal"><name><surname>Kanchan</surname><given-names>K</given-names></name>, <name><surname>Fuxreiter</surname><given-names>M</given-names></name>, <name><surname>Fesus</surname><given-names>L</given-names></name>. <article-title>Physiological, pathological, and structural implications of nonenzymatic protein–protein interactions of the multifunctional human transglutaminase 2</article-title>. <source/>Cell Mol Life Sci. <year>2015</year>;<volume>72</volume>(<issue>16</issue>): <fpage>3009</fpage>–<lpage>3035</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-015-1909-z</pub-id>
<pub-id pub-id-type="pmid">25943306</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref005">
<label>5</label>
<mixed-citation publication-type="journal"><name><surname>Eckert</surname><given-names>RL</given-names></name>, <name><surname>Kaartinen</surname><given-names>MT</given-names></name>, <name><surname>Nurminskaya</surname><given-names>M</given-names></name>, <name><surname>Belkin</surname><given-names>AM</given-names></name>, <name><surname>Colak</surname><given-names>G</given-names></name>, <name><surname>Johnson</surname><given-names>GVW</given-names></name>, <etal>et al</etal>
<article-title>Transglutaminase regulation of cell function</article-title>. <source/>Physiol Rev. <year>2014</year>; <volume>94</volume>: <fpage>383</fpage>–<lpage>417</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00019.2013</pub-id>
<pub-id pub-id-type="pmid">24692352</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref006">
<label>6</label>
<mixed-citation publication-type="journal"><name><surname>Iismaa</surname><given-names>SE</given-names></name>, <name><surname>Aplin</surname><given-names>M</given-names></name>, <name><surname>Holman</surname><given-names>S</given-names></name>, <name><surname>Yiu</surname><given-names>TW</given-names></name>, <name><surname>Jackson</surname><given-names>K</given-names></name>, <name><surname>Burchfield</surname><given-names>JG</given-names></name>, <etal>et al</etal>
<article-title>Glucose Homeostasis in Mice Is Transglutaminase 2 Independent</article-title>. <source/>PLoS One. <year>2013</year>;<volume>8</volume>(<issue>5</issue>): <fpage>e63346</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0063346</pub-id>
<pub-id pub-id-type="pmid">23717413</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref007">
<label>7</label>
<mixed-citation publication-type="journal"><name><surname>Ng</surname><given-names>SB</given-names></name>, <name><surname>Buckingham</surname><given-names>KJ</given-names></name>, <name><surname>Lee</surname><given-names>C</given-names></name>, <name><surname>Bigham</surname><given-names>AW</given-names></name>, <name><surname>Tabor</surname><given-names>HK</given-names></name>, <name><surname>Dent</surname><given-names>KM</given-names></name>, <etal>et al</etal>
<article-title>Exome sequencing identifies the cause of a Mendelian disorder</article-title>. <source/>Nat Genet. <year>2010</year>;<volume>42</volume>(<issue>1</issue>): <fpage>30</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1038/ng.499</pub-id>
<pub-id pub-id-type="pmid">19915526</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref008">
<label>8</label>
<mixed-citation publication-type="journal"><name><surname>Ramensky</surname><given-names>V</given-names></name>, <name><surname>Bork</surname><given-names>P</given-names></name>, <name><surname>Sunyaev</surname><given-names>S</given-names></name>. <article-title>Human non-synonymous SNPs: server and survey</article-title>. <source/>Nucleic Acids Res. <year>2002</year>;<volume>30</volume>(<issue>17</issue>): <fpage>3894</fpage>–<lpage>3900</lpage>. <pub-id pub-id-type="pmid">12202775</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref009">
<label>9</label>
<mixed-citation publication-type="journal"><name><surname>Tennessen</surname><given-names>JA</given-names></name>, <name><surname>Bigham</surname><given-names>AW</given-names></name>, <name><surname>O'Connor</surname><given-names>TD</given-names></name>, <name><surname>Fu</surname><given-names>W</given-names></name>, <name><surname>Kenny</surname><given-names>EE</given-names></name>, <name><surname>Gravel</surname><given-names>S</given-names></name>, <etal>et al</etal>, <name><surname>Broad</surname><given-names>GO</given-names></name>, <name><surname>Seattle</surname><given-names>GO</given-names></name>, <collab>on behalf of the NHLBI Exome Sequencing Project</collab>. <article-title>Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes</article-title>. <source/>Science. <year>2012</year>;<volume>337</volume>(<issue>6090</issue>): <fpage>64</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1126/science.1219240</pub-id>
<pub-id pub-id-type="pmid">22604720</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref010">
<label>10</label>
<mixed-citation publication-type="journal"><name><surname>Sulem</surname><given-names>P</given-names></name>, <name><surname>Helgason</surname><given-names>H</given-names></name>, <name><surname>Oddson</surname><given-names>A</given-names></name>, <name><surname>Stefansson</surname><given-names>H</given-names></name>, <name><surname>Gudjonsson</surname><given-names>SA</given-names></name>, <name><surname>Zink</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Identification of a large set of rare complete human knockouts</article-title>. <source/>Nat Genet. <year>2015</year>;<volume>47</volume>(<issue>5</issue>): <fpage>448</fpage>–<lpage>452</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3243</pub-id>
<pub-id pub-id-type="pmid">25807282</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref011">
<label>11</label>
<mixed-citation publication-type="journal"><name><surname>Lek</surname><given-names>M</given-names></name>, <name><surname>Karczewski</surname><given-names>K</given-names></name>, <name><surname>Minikel</surname><given-names>E</given-names></name>, <name><surname>Samocha</surname><given-names>K</given-names></name>, <name><surname>Banks</surname><given-names>E</given-names></name>, <name><surname>Fennell</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source/>Nature. <year>2016</year>;<volume>536</volume>: <fpage>285</fpage>–<lpage>291</lpage>. <pub-id pub-id-type="doi">10.1038/nature19057</pub-id>
<pub-id pub-id-type="pmid">27535533</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref012">
<label>12</label>
<mixed-citation publication-type="journal"><name><surname>Narasimhan</surname><given-names>VM</given-names></name>, <name><surname>Hunt</surname><given-names>KA</given-names></name>, <name><surname>Mason</surname><given-names>D</given-names></name>, <name><surname>Baker</surname><given-names>CL</given-names></name>, <name><surname>Karczewski</surname><given-names>KJ</given-names></name>, <name><surname>Barnes</surname><given-names>MR</given-names></name>, <etal>et al</etal>
<article-title>Health and population effects of rare gene knockouts in adult humans with related parents</article-title>. <source/>Science. <year>2016</year>;<volume>352</volume>(<issue>6284</issue>):<fpage>474</fpage>–<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1126/science.aac8624</pub-id>
<pub-id pub-id-type="pmid">26940866</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref013">
<label>13</label>
<mixed-citation publication-type="journal"><name><surname>Blomen</surname><given-names>VA</given-names></name>, <name><surname>Majek</surname><given-names>P</given-names></name>, <name><surname>Jae</surname><given-names>LT</given-names></name>, <name><surname>Bigenzahn</surname><given-names>JW</given-names></name>, <name><surname>Nieuwenhuis</surname><given-names>J</given-names></name>, <name><surname>Staring</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Gene essentiality and synthetic lethality in haploid human cells</article-title>. <source/>Science. <year>2015</year>;<volume>350</volume>(<issue>6264</issue>): <fpage>1092</fpage>–<lpage>1096</lpage>. <pub-id pub-id-type="doi">10.1126/science.aac7557</pub-id>
<pub-id pub-id-type="pmid">26472760</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref014">
<label>14</label>
<mixed-citation publication-type="journal"><name><surname>Hart</surname><given-names>T</given-names></name>, <name><surname>Chandrashekhar</surname><given-names>M</given-names></name>, <name><surname>Aregger</surname><given-names>M</given-names></name>, <name><surname>Steinhart</surname><given-names>Z</given-names></name>, <name><surname>Brown</surname><given-names>KR</given-names></name>, <name><surname>MacLeod</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities</article-title>. <source/>Cell. <year>2015</year>;<volume>163</volume>(<issue>6</issue>): <fpage>1515</fpage>–<lpage>1526</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.11.015</pub-id>
<pub-id pub-id-type="pmid">26627737</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref015">
<label>15</label>
<mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>T</given-names></name>, <name><surname>Birsoy</surname><given-names>K</given-names></name>, <name><surname>Hughes</surname><given-names>NW</given-names></name>, <name><surname>Krupczak</surname><given-names>KM</given-names></name>, <name><surname>Post</surname><given-names>Y</given-names></name>, <name><surname>Wei</surname><given-names>JJ</given-names></name>, <etal>et al</etal>
<article-title>Identification and characterization of essential genes in the human genome</article-title>. <source/>Science. <year>2015</year>;<volume>350</volume>(<issue>6264</issue>): <fpage>1096</fpage>–<lpage>1101</lpage>. <pub-id pub-id-type="doi">10.1126/science.aac7041</pub-id>
<pub-id pub-id-type="pmid">26472758</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref016">
<label>16</label>
<mixed-citation publication-type="journal"><name><surname>Király</surname><given-names>R</given-names></name>, <name><surname>Barta</surname><given-names>E</given-names></name>, <name><surname>Fésüs</surname><given-names>L</given-names></name>. <article-title>Polymorphism of transglutaminase 2: unusually low frequency of genomic variants with deficient functions</article-title>. <source/>Amino Acids. <year>2013</year>;<volume>44</volume>: <fpage>215</fpage>–<lpage>225</lpage>. <pub-id pub-id-type="doi">10.1007/s00726-011-1194-6</pub-id>
<pub-id pub-id-type="pmid">22160262</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref017">
<label>17</label>
<mixed-citation publication-type="journal"><name><surname>Biri</surname><given-names>B</given-names></name>, <name><surname>Kiss</surname><given-names>B</given-names></name>, <name><surname>Király</surname><given-names>R</given-names></name>, <name><surname>Schlosser</surname><given-names>G</given-names></name>, <name><surname>Lang</surname><given-names>O</given-names></name>, <name><surname>Kohidai</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Metastasis-associated S100A4 is a specific amine donor and an activity independent binding partner of transglutaminase-2</article-title>. <source/>Biochem J. <year>2016</year>;<volume>473</volume>(<issue>1</issue>): <fpage>31</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20150843</pub-id>
<pub-id pub-id-type="pmid">26487698</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref018">
<label>18</label>
<mixed-citation publication-type="journal"><name><surname>Thangaraju</surname><given-names>K</given-names></name>, <name><surname>Biri</surname><given-names>B</given-names></name>, <name><surname>Schlosser</surname><given-names>G</given-names></name>, <name><surname>Kiss</surname><given-names>B</given-names></name>, <name><surname>Nyitray</surname><given-names>L</given-names></name>, <name><surname>Fesüs</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Real-time kinetic method to monitor isopeptidase activity of transglutaminase 2 on protein substrate</article-title>. <source/>Anal. Biochem.
<year>2016</year>;<volume>505</volume>: <fpage>36</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.ab.2016.04.012</pub-id>
<pub-id pub-id-type="pmid">27131890</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref019">
<label>19</label>
<mixed-citation publication-type="journal"><name><surname>Dinkel</surname><given-names>H</given-names></name>, <name><surname>Roey</surname><given-names>KV</given-names></name>, <name><surname>Michael</surname><given-names>S</given-names></name>, <name><surname>Davey</surname><given-names>NE</given-names></name>, <name><surname>Weatheritt</surname><given-names>RJ</given-names></name>, <name><surname>Born</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>The eukaryotic linear motif resource ELM: 10 years and counting</article-title>. <source/>Nucleic Acids Res. <year>2014</year>;<volume>42</volume> (database issue): <fpage>D259</fpage>–<lpage>266</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1047</pub-id>
<pub-id pub-id-type="pmid">24214962</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref020">
<label>20</label>
<mixed-citation publication-type="journal"><name><surname>Samocha</surname><given-names>KE</given-names></name>, <name><surname>Robinson</surname><given-names>EB</given-names></name>, <name><surname>Sanders</surname><given-names>SJ</given-names></name>, <name><surname>Stevens</surname><given-names>C</given-names></name>, <name><surname>Sabo</surname><given-names>A</given-names></name>, <name><surname>McGrath</surname><given-names>LM</given-names></name>, <etal>et al</etal>
<article-title>A framework for the interpretation of de novo mutation in human disease</article-title>. <source/>Nat Genet. <year>2014</year>; <volume>46</volume>(<issue>9</issue>): <fpage>944</fpage>–<lpage>950</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3050</pub-id>
<pub-id pub-id-type="pmid">25086666</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref021">
<label>21</label>
<mixed-citation publication-type="journal"><name><surname>Itan</surname><given-names>Y</given-names></name>, <name><surname>Shang</surname><given-names>L</given-names></name>, <name><surname>Boisson</surname><given-names>B</given-names></name>, <name><surname>Patin</surname><given-names>E</given-names></name>, <name><surname>Bolze</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>The human gene damage index as a gene-level approach to prioritizing exome variants</article-title>. <source/>Proc Natl Acad Sci U S A. <year>2015</year>;<volume>112</volume>(<issue>44</issue>): <fpage>13615</fpage>–<lpage>13620</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1518646112</pub-id>
<pub-id pub-id-type="pmid">26483451</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref022">
<label>22</label>
<mixed-citation publication-type="journal"><name><surname>Thomas</surname><given-names>PD</given-names></name>, <name><surname>Campbell</surname><given-names>MJ</given-names></name>, <name><surname>Kejariwal</surname><given-names>A</given-names></name>, <name><surname>Mi</surname><given-names>H</given-names></name>, <name><surname>Karlak</surname><given-names>B</given-names></name>, <name><surname>Daverman</surname><given-names>R</given-names></name>, <article-title>PANTHER: A Library of Protein Families and Subfamilies Indexed by Function</article-title>. <source/>Genome Res. <year>2003</year>;<volume>13</volume>(<issue>9</issue>): <fpage>2129</fpage>–<lpage>2141</lpage>. <pub-id pub-id-type="doi">10.1101/gr.772403</pub-id>
<pub-id pub-id-type="pmid">12952881</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref023">
<label>23</label>
<mixed-citation publication-type="journal"><name><surname>Guerois</surname><given-names>R</given-names></name>, <name><surname>Nielsen</surname><given-names>JE</given-names></name>, <name><surname>Serrano</surname><given-names>L</given-names></name>. <article-title>Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations</article-title>. <source/>J Mol Biol. <year>2002</year>;<volume>320</volume>(<issue>2</issue>): <fpage>369</fpage>–<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-2836(02)00442-4</pub-id>
<pub-id pub-id-type="pmid">12079393</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref024">
<label>24</label>
<mixed-citation publication-type="journal"><name><surname>Ahvazi</surname><given-names>B</given-names></name>, <name><surname>Kim</surname><given-names>HC</given-names></name>, <name><surname>Kee</surname><given-names>SH</given-names></name>, <name><surname>Nemes</surname><given-names>Z</given-names></name>, <name><surname>Steinert</surname><given-names>PM</given-names></name>. <article-title>Three-dimensional structure of the human transglutaminase 3 enzyme: binding of calcium ions changes structure for activation</article-title>. <source/>EMBO J. <year>2002</year>;<volume>21</volume>: <fpage>2055</fpage>–<lpage>2067</lpage>
<pub-id pub-id-type="doi">10.1093/emboj/21.9.2055</pub-id>
<pub-id pub-id-type="pmid">11980702</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref025">
<label>25</label>
<mixed-citation publication-type="journal"><name><surname>Arnold</surname><given-names>K</given-names></name>, <name><surname>Bordoli</surname><given-names>L</given-names></name>, <name><surname>Kopp</surname><given-names>J</given-names></name>, and <name><surname>Schwede</surname><given-names>T</given-names></name>. <article-title>The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling</article-title>. <source/>Bioinformatics. <year>2006</year>;<volume>22</volume>: <fpage>195</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bti770</pub-id>
<pub-id pub-id-type="pmid">16301204</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref026">
<label>26</label>
<mixed-citation publication-type="journal"><name><surname>Stieler</surname><given-names>M</given-names></name>, <name><surname>Weber</surname><given-names>J</given-names></name>, <name><surname>Hils</surname><given-names>M</given-names></name>, <name><surname>Kolb</surname><given-names>P</given-names></name>, <name><surname>Heine</surname><given-names>A</given-names></name>, <name><surname>Buchold</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Structure of Active Coagulation Factor XIII Triggered by Calcium Binding: Basis for the Design of Next-Generation Anticoagulants</article-title>. <source/>Angewandte Chemie. International Edition English. <year>2013</year>;<volume>52</volume>: <fpage>11930</fpage>–<lpage>11934</lpage>.</mixed-citation>
</ref>
<ref id="pone.0172189.ref027">
<label>27</label>
<mixed-citation publication-type="journal"><name><surname>Krieger</surname><given-names>E</given-names></name>, <name><surname>Vriend</surname><given-names>G</given-names></name>. <article-title>Models@Home: distributed computing in bioinformatics using a screensaver based approach</article-title>. <source/>Bioinformatics. <year>2002</year>;<volume>18</volume>(<issue>2</issue>): <fpage>315</fpage>–<lpage>318</lpage>. <pub-id pub-id-type="pmid">11847079</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref028">
<label>28</label>
<mixed-citation publication-type="journal"><name><surname>Schymkowitz</surname><given-names>J</given-names></name>, <name><surname>Borg</surname><given-names>J</given-names></name>, <name><surname>Stricher</surname><given-names>F</given-names></name>, <name><surname>Nys</surname><given-names>R</given-names></name>, <name><surname>Rousseau</surname><given-names>F</given-names></name>, <name><surname>Serrano</surname><given-names>L</given-names></name>. <article-title>The FoldX web server: an online force field</article-title>. <source/>Nucleic Acids Res. <year>2005</year>;<volume>33</volume>: <fpage>W382</fpage>–<lpage>388</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gki387</pub-id>
<pub-id pub-id-type="pmid">15980494</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref029">
<label>29</label>
<mixed-citation publication-type="journal"><name><surname>Király</surname><given-names>R</given-names></name>, <name><surname>Thangaraju</surname><given-names>K</given-names></name>, <name><surname>Nagy</surname><given-names>Z</given-names></name>, <name><surname>Collighan</surname><given-names>R</given-names></name>, <name><surname>Nemes</surname><given-names>Z</given-names></name>, <name><surname>Griffin</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Isopeptidase activity of human transglutaminase 2: disconnection from transamidation and characterization by kinetic parameters</article-title>. <source/>Amino Acids. <year>2016</year>;<volume>48</volume>(<issue>1</issue>): <fpage>31</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1007/s00726-015-2063-5</pub-id>
<pub-id pub-id-type="pmid">26250429</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref030">
<label>30</label>
<mixed-citation publication-type="journal"><name><surname>Thangaraju</surname><given-names>K</given-names></name>, <name><surname>Király</surname><given-names>R</given-names></name>, <name><surname>Mótyán</surname><given-names>JA</given-names></name>, <name><surname>Ambrus</surname><given-names>VA</given-names></name>, <name><surname>Fuxreiter</surname><given-names>M</given-names></name>, <name><surname>Fésüs</surname><given-names>L</given-names></name>. <article-title>Computational analyses of the effect of novel amino acid clusters of human transglutaminase 2 on its structure and function</article-title>. <source/>Amino acids. <year>2016</year>;</mixed-citation>
</ref>
<ref id="pone.0172189.ref031">
<label>31</label>
<mixed-citation publication-type="journal"><name><surname>Cardoso</surname><given-names>I</given-names></name>, <name><surname>Østerlund</surname><given-names>EC</given-names></name>, <name><surname>Stamnaes</surname><given-names>J</given-names></name>, <name><surname>Iversen</surname><given-names>R</given-names></name>, <name><surname>Andersen</surname><given-names>JT</given-names></name>, <name><surname>Jørgensen</surname><given-names>TJD</given-names></name>, <etal>et al</etal>
<article-title>Dissecting the interaction between transglutaminase 2 and fibronectin</article-title>. <source/>Amino Acids. <year>2016</year>;</mixed-citation>
</ref>
<ref id="pone.0172189.ref032">
<label>32</label>
<mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>S</given-names></name>, <name><surname>Cerione</surname><given-names>RA</given-names></name>, <name><surname>Clardy</surname><given-names>J</given-names></name>. <article-title>Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity</article-title>. <source/>Proc Natl Acad Sci U S A. <year>2002</year>;<volume>99</volume>(<issue>5</issue>): <fpage>2743</fpage>–<lpage>2747</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.042454899</pub-id>
<pub-id pub-id-type="pmid">11867708</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref033">
<label>33</label>
<mixed-citation publication-type="journal"><name><surname>Király</surname><given-names>R</given-names></name>, <name><surname>Csosz</surname><given-names>E</given-names></name>, <name><surname>Kurtán</surname><given-names>T</given-names></name>, <name><surname>Antus</surname><given-names>S</given-names></name>, <name><surname>Szigeti</surname><given-names>K</given-names></name>, <name><surname>Simon-Vecsei</surname><given-names>Z</given-names></name>, <etal>et al</etal>
<article-title>Functional significance of five noncanonical Ca<sup>2+</sup>-binding sites of human transglutaminase 2 characterized by site-directed mutagenesis</article-title>. <source/>FEBS Journal. <year>2009</year>;<volume>276</volume>(<issue>23</issue>): <fpage>7083</fpage>–<lpage>7096</lpage>. <pub-id pub-id-type="doi">10.1111/j.1742-4658.2009.07420.x</pub-id>
<pub-id pub-id-type="pmid">19878304</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref034">
<label>34</label>
<mixed-citation publication-type="journal"><name><surname>Muszbek</surname><given-names>L</given-names></name>, <name><surname>Bereczky</surname><given-names>Z</given-names></name>, <name><surname>Bagoly</surname><given-names>Z</given-names></name>, <name><surname>Komáromi</surname><given-names>I</given-names></name>, <name><surname>Katona</surname><given-names>É</given-names></name>. <article-title>Factor XIII: a coagulation factor with multiple plasmatic and cellular functions</article-title>. <source/>Physiol Rev. <year>2011</year>;<volume>91</volume>: <fpage>931</fpage>–<lpage>972</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00016.2010</pub-id>
<pub-id pub-id-type="pmid">21742792</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref035">
<label>35</label>
<mixed-citation publication-type="journal"><name><surname>Han</surname><given-names>Y</given-names></name>, <name><surname>Tung</surname><given-names>TQ</given-names></name>, <name><surname>Ann</surname><given-names>I</given-names></name>. <article-title>Computational approaches for identifying deleterious nonsynonymous variants from human genomes</article-title>. <source/>Advanced Science and Technology Letters. <year>2015</year>;<volume>105</volume>: <fpage>44</fpage>–<lpage>48</lpage>.</mixed-citation>
</ref>
<ref id="pone.0172189.ref036">
<label>36</label>
<mixed-citation publication-type="journal"><name><surname>Tokuriki</surname><given-names>N</given-names></name>, <name><surname>Stricher</surname><given-names>F</given-names></name>, <name><surname>Schymkowitz</surname><given-names>J</given-names></name>, <name><surname>Serrano</surname><given-names>L</given-names></name>, <name><surname>Taw</surname><given-names>DS</given-names></name>. <article-title>The Stability Effects of Protein Mutations Appear to be Universally Distributed</article-title>. <source/>J Mol Biol. <year>2007</year>;<volume>369</volume>: <fpage>1318</fpage>–<lpage>1332</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2007.03.069</pub-id>
<pub-id pub-id-type="pmid">17482644</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref037">
<label>37</label>
<mixed-citation publication-type="journal"><name><surname>Tokuriki</surname><given-names>N</given-names></name>, <name><surname>Tawfik</surname><given-names>DS</given-names></name>. <article-title>Stability effects of mutations and protein evolvability</article-title>. <source/>Curr Opin Struct Biol. <year>2009</year>;<volume>19</volume>(<issue>5</issue>): <fpage>596</fpage>–<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1016/j.sbi.2009.08.003</pub-id>
<pub-id pub-id-type="pmid">19765975</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref038">
<label>38</label>
<mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Collighan</surname><given-names>RJ</given-names></name>, <name><surname>Pytel</surname><given-names>K</given-names></name>, <name><surname>Rathbone</surname><given-names>DL</given-names></name>, <name><surname>Li</surname><given-names>X</given-names></name>, <name><surname>Griffin</surname><given-names>M</given-names></name>. <article-title>Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signalling</article-title>. <source/>J Biol Chem. <year>2012</year>;<volume>287</volume>(<issue>16</issue>): <fpage>13063</fpage>–<lpage>13083</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.294819</pub-id>
<pub-id pub-id-type="pmid">22298777</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref039">
<label>39</label>
<mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>Z</given-names></name>, <name><surname>Telci</surname><given-names>D</given-names></name>, <name><surname>Griffin</surname><given-names>M</given-names></name>. <article-title>Importance of syndecan-4 and syndecan-2 in osteoblast cell adhesion and survival mediated by a tissue transglutaminase–fibronectin complex</article-title>. <source/>Exp Cell Res. <year>2011</year>;<volume>317</volume>(<issue>3</issue>): <fpage>367</fpage>–<lpage>381</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2010.10.015</pub-id>
<pub-id pub-id-type="pmid">21036168</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref040">
<label>40</label>
<mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>S</given-names></name>, <name><surname>Lin</surname><given-names>F</given-names></name>, <name><surname>Iismaa</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>KN</given-names></name>, <name><surname>Birckbichler</surname><given-names>PJ</given-names></name>, <name><surname>Graham</surname><given-names>RM</given-names></name>. <article-title>Alpha1-adrenergic receptor signalling via Gh is subtype specific and independent of its transglutaminase activity</article-title>. <source/>J Biol Chem. <year>1996</year>;<volume>271</volume>(<issue>50</issue>): <fpage>32385</fpage>–<lpage>32391</lpage>. <pub-id pub-id-type="pmid">8943303</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref041">
<label>41</label>
<mixed-citation publication-type="journal"><name><surname>Feng</surname><given-names>JF</given-names></name>, <name><surname>Gray</surname><given-names>CD</given-names></name>, <name><surname>Im</surname><given-names>MJ</given-names></name>. <article-title>Alpha 1B-adrenoceptor interacts with multiple sites of transglutaminase II: characteristics of the interaction in binding and activation</article-title>. <source/>Biochemistry. <year>1999</year>;<volume>38</volume>(<issue>7</issue>): <fpage>2224</fpage>–<lpage>2232</lpage>. <pub-id pub-id-type="doi">10.1021/bi9823176</pub-id>
<pub-id pub-id-type="pmid">10026307</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref042">
<label>42</label>
<mixed-citation publication-type="journal"><name><surname>Hwang</surname><given-names>KC</given-names></name>, <name><surname>Gray</surname><given-names>CD</given-names></name>, <name><surname>Sivasubramanian</surname><given-names>N</given-names></name>, <name><surname>Im</surname><given-names>MJ</given-names></name>. <article-title>Interaction site of GTP binding Gh (transglutaminase II) with phospholipase C</article-title>. <source/>J Biol Chem. <year>1995</year>;<volume>270</volume>(<issue>45</issue>): <fpage>27058</fpage>–<lpage>27062</lpage>. <pub-id pub-id-type="pmid">7592956</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref043">
<label>43</label>
<mixed-citation publication-type="journal"><name><surname>Kang</surname><given-names>SK</given-names></name>, <name><surname>Kim</surname><given-names>DK</given-names></name>, <name><surname>Damron</surname><given-names>DS</given-names></name>, <name><surname>Baek</surname><given-names>KJ</given-names></name>, <name><surname>Im</surname><given-names>MJ</given-names></name>. <article-title>Modulation of intracellular Ca(2+) via alpha(1B)-adrenoreceptor signalling molecules, G alpha(h) (transglutaminase II) and phospholipase C-delta 1</article-title>. <source/>Biochem Biophys Res Commun. <year>2002</year>;<volume>293</volume>(<issue>1</issue>): <fpage>383</fpage>–<lpage>390</lpage>. <pub-id pub-id-type="doi">10.1016/S0006-291X(02)00197-3</pub-id>
<pub-id pub-id-type="pmid">12054611</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref044">
<label>44</label>
<mixed-citation publication-type="journal"><name><surname>Rodolfo</surname><given-names>C</given-names></name>, <name><surname>Mormone</surname><given-names>E</given-names></name>, <name><surname>Matarrese</surname><given-names>P</given-names></name>, <name><surname>Ciccosanti</surname><given-names>F</given-names></name>, <name><surname>Farrace</surname><given-names>MG</given-names></name>, <name><surname>Garofano</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Tissue transglutaminase is a multifunctional BH3-only protein</article-title>. <source/>J Biol Chem. <year>2004</year>;<volume>279</volume>(<issue>52</issue>): <fpage>54783</fpage>–<lpage>54792</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M410938200</pub-id>
<pub-id pub-id-type="pmid">15485857</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref045">
<label>45</label>
<mixed-citation publication-type="journal"><name><surname>Mishra</surname><given-names>S</given-names></name>, <name><surname>Murphy</surname><given-names>LJ</given-names></name>. <article-title>Phosphorylation of transglutaminase 2 by PKA at Ser216 creates 14-3-3 binding sites</article-title>. <source/>Biochem Biophys Res Commun. <year>2006</year>;<volume>347</volume>(<issue>4</issue>): <fpage>1166</fpage>–<lpage>1170</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2006.07.041</pub-id>
<pub-id pub-id-type="pmid">16870138</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref046">
<label>46</label>
<mixed-citation publication-type="journal"><name><surname>Luciani</surname><given-names>A</given-names></name>, <name><surname>Villella</surname><given-names>VR</given-names></name>, <name><surname>Vasaturo</surname><given-names>A</given-names></name>, <name><surname>Giardino</surname><given-names>I</given-names></name>, <name><surname>Raia</surname><given-names>V</given-names></name>, <name><surname>Mantovani</surname><given-names>MP</given-names></name>, <etal>et al</etal>
<article-title>SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation</article-title>. <source/>J Immunol. <year>2009</year>;<volume>183</volume>(<issue>4</issue>): <fpage>2775</fpage>–<lpage>2784</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0900993</pub-id>
<pub-id pub-id-type="pmid">19625650</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref047">
<label>47</label>
<mixed-citation publication-type="journal"><name><surname>Porzio</surname><given-names>O</given-names></name>, <name><surname>Massa</surname><given-names>O</given-names></name>, <name><surname>Cunsolo</surname><given-names>V</given-names></name>, <name><surname>Colombo</surname><given-names>C</given-names></name>, <name><surname>Malaponti</surname><given-names>M</given-names></name>, <name><surname>Bertuzzi</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Missense mutations in the TGM2 gene encoding Transglutaminase 2 are found in patients with early-onset Type 2 diabetes</article-title>. <source/>Hum Mutat. <year>2007</year>;<volume>28</volume>(<issue>11</issue>): <fpage>1150</fpage>.</mixed-citation>
</ref>
<ref id="pone.0172189.ref048">
<label>48</label>
<mixed-citation publication-type="journal"><name><surname>Iismaa</surname><given-names>SE</given-names></name>, <name><surname>Mearns</surname><given-names>BM</given-names></name>, <name><surname>Lorand</surname><given-names>L</given-names></name>, <name><surname>Graham</surname><given-names>RM</given-names></name>. <article-title>Transglutaminases and Disease: Lessons From Genetically Engineered Mouse Models and Inherited Disorders</article-title>. <source/>Physiol Rev. <year>2009</year>;<volume>89</volume>(<issue>3</issue>): <fpage>991</fpage>–<lpage>1023</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00044.2008</pub-id>
<pub-id pub-id-type="pmid">19584319</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref049">
<label>49</label>
<mixed-citation publication-type="journal"><name><surname>Iversen</surname><given-names>R</given-names></name>, <name><surname>Mysling</surname><given-names>S</given-names></name>, <name><surname>Hnida</surname><given-names>K</given-names></name>, <name><surname>Jørgensen</surname><given-names>TJD</given-names></name>, <name><surname>Sollid</surname><given-names>LM</given-names></name>. <article-title>Activity-regulating structural changes and autoantibody epitopes in transglutaminase 2 assessed by hydrogen/deuterium exchange</article-title>. <source/>Proc Natl Acad Sci U S A. <year>2014</year>;<volume>111</volume>(<issue>48</issue>): <fpage>17146</fpage>–<lpage>17151</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1407457111</pub-id>
<pub-id pub-id-type="pmid">25404341</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref050">
<label>50</label>
<mixed-citation publication-type="journal"><name><surname>Simon-Vecsei</surname><given-names>Z</given-names></name>, <name><surname>Király</surname><given-names>R</given-names></name>, <name><surname>Bagossi</surname><given-names>P</given-names></name>, <name><surname>Tóth</surname><given-names>B</given-names></name>, <name><surname>Dahlbom</surname><given-names>I</given-names></name>, <name><surname>Caja</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>A single conformational transglutaminase 2 epitope contributed by three domains is critical for celiac antibody binding and effects</article-title>. <source/>Proc Natl Acad Sci U S A. <year>2012</year>;<volume>109</volume>(<issue>2</issue>): <fpage>431</fpage>–<lpage>436</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1107811108</pub-id>
<pub-id pub-id-type="pmid">22198767</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref051">
<label>51</label>
<mixed-citation publication-type="journal"><name><surname>Davey</surname><given-names>NE</given-names></name>, <name><surname>Van Roey</surname><given-names>K</given-names></name>, <name><surname>Weatheritt</surname><given-names>RJ</given-names></name>, <name><surname>Toedt</surname><given-names>G</given-names></name>, <name><surname>Uyar</surname><given-names>B</given-names></name>, <name><surname>Altenberg</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Attributes of short linear motifs</article-title>. <source/>Molecular BioSystems. <year>2012</year>;<volume>8</volume>(<issue>1</issue>): <fpage>268</fpage>–<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1039/c1mb05231d</pub-id>
<pub-id pub-id-type="pmid">21909575</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref052">
<label>52</label>
<mixed-citation publication-type="journal"><name><surname>Kalvari</surname><given-names>I</given-names></name>, <name><surname>Tsompanis</surname><given-names>S</given-names></name>, <name><surname>Mulakkal</surname><given-names>NC</given-names></name>, <name><surname>Osgood</surname><given-names>R</given-names></name>, <name><surname>Johansen</surname><given-names>T</given-names></name>, <name><surname>Nezis</surname><given-names>IP</given-names></name>, <etal>et al</etal>
<article-title>iLIR: A web resource for prediction of Atg8-family interacting proteins</article-title>. <source/>Autophagy. <year>2014</year>;<volume>10</volume>(<issue>5</issue>): <fpage>913</fpage>–<lpage>925</lpage>. <pub-id pub-id-type="doi">10.4161/auto.28260</pub-id>
<pub-id pub-id-type="pmid">24589857</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref053">
<label>53</label>
<mixed-citation publication-type="journal"><name><surname>D'Eletto</surname><given-names>M</given-names></name>, <name><surname>Farrace</surname><given-names>MG</given-names></name>, <name><surname>Falasca</surname><given-names>L</given-names></name>, <name><surname>Reali</surname><given-names>V</given-names></name>, <name><surname>Oliverio</surname><given-names>S</given-names></name>, <name><surname>Melino</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Transglutaminase 2 is involved in autophagosome maturation</article-title>. <source/>Autophagy. <year>2009</year>;<volume>5</volume>(<issue>8</issue>): <fpage>1145</fpage>–<lpage>1154</lpage>. <pub-id pub-id-type="pmid">19955852</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref054">
<label>54</label>
<mixed-citation publication-type="journal"><name><surname>D'Eletto</surname><given-names>M</given-names></name>, <name><surname>Farrace</surname><given-names>MG</given-names></name>, <name><surname>Rossin</surname><given-names>F</given-names></name>, <name><surname>Strappazzon</surname><given-names>F</given-names></name>, <name><surname>Di Giacomo</surname><given-names>G</given-names></name>, <name><surname>Cecconi</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Type 2 transglutaminase is involved in the autophagy-dependent clearance of ubiquitinated proteins</article-title>. <source/>Cell Death &amp; Differentiation. <year>2012</year>;<volume>19</volume>(<issue>7</issue>): <fpage>1228</fpage>–<lpage>1238</lpage>.<pub-id pub-id-type="pmid">22322858</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref055">
<label>55</label>
<mixed-citation publication-type="journal"><name><surname>Greg</surname><given-names>G</given-names></name>. <article-title>Rare and common variants: twenty arguments</article-title>. <source/>Nature Review Genetics. <year>2012</year>;<volume>13</volume>: <fpage>135</fpage>–<lpage>145</lpage>.</mixed-citation>
</ref>
<ref id="pone.0172189.ref056">
<label>56</label>
<mixed-citation publication-type="journal"><name><surname>Lorand L Stern</surname><given-names>AM</given-names></name>, <name><surname>Velasco</surname><given-names>PT</given-names></name>. <article-title>Novel inhibitors against the transglutaminase-catalysed crosslinking of lens proteins</article-title>. <source/>Exp Eye Res. <year>1998</year>;<volume>66</volume>: <fpage>531</fpage>–<lpage>536</lpage>. <pub-id pub-id-type="doi">10.1006/exer.1997.0463</pub-id>
<pub-id pub-id-type="pmid">9628800</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref057">
<label>57</label>
<mixed-citation publication-type="journal"><name><surname>MacArthur</surname><given-names>DG</given-names></name>, <name><surname>Balasubramanian</surname><given-names>S</given-names></name>, <name><surname>Frankish</surname><given-names>A</given-names></name>, <name><surname>Huang</surname><given-names>N</given-names></name>, <name><surname>Morris</surname><given-names>J</given-names></name>, <name><surname>Walter</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>A systematic survey of loss-of-function variants in human protein-coding genes</article-title>. <source/>Science. <year>2012</year>;<volume>335</volume>(<issue>6070</issue>): <fpage>823</fpage>–<lpage>828</lpage>. <pub-id pub-id-type="doi">10.1126/science.1215040</pub-id>
<pub-id pub-id-type="pmid">22344438</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref058">
<label>58</label>
<mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>AH</given-names></name>, <name><surname>Morrison</surname><given-names>AC</given-names></name>, <name><surname>Kovar</surname><given-names>C</given-names></name>, <name><surname>Cupples</surname><given-names>LA</given-names></name>, <name><surname>Brody</surname><given-names>JA</given-names></name>, <name><surname>Polfus</surname><given-names>LM</given-names></name>, <etal>et al</etal>
<article-title>Analysis of loss-of-function variants and 20 risk factor phenotypes in 8,554 individuals identifies loci influencing chronic disease</article-title>. <source/>Nat Genet. <year>2015</year>;<volume>47</volume>(<issue>6</issue>): <fpage>640</fpage>–<lpage>642</lpage>
<pub-id pub-id-type="doi">10.1038/ng.3270</pub-id>
<pub-id pub-id-type="pmid">25915599</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref059">
<label>59</label>
<mixed-citation publication-type="journal"><name><surname>Lim</surname><given-names>ET</given-names></name>, <name><surname>Raychaudhuri</surname><given-names>S</given-names></name>, <name><surname>Sanders</surname><given-names>SJ</given-names></name>, <name><surname>Stevens</surname><given-names>C</given-names></name>, <name><surname>Sabo</surname><given-names>A</given-names></name>, <name><surname>MacArthur</surname><given-names>DG</given-names></name>, <etal>et al</etal>
<article-title>Rare complete knockouts in humans: population distribution and significant role in autism spectrum disorders</article-title>. <source/>Neuron. <year>2013</year>;<volume>77</volume>(<issue>2</issue>): <fpage>235</fpage>–<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2012.12.029</pub-id>
<pub-id pub-id-type="pmid">23352160</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref060">
<label>60</label>
<mixed-citation publication-type="journal"><name><surname>Kohler</surname><given-names>HP</given-names></name>, <name><surname>Stickland</surname><given-names>MH</given-names></name>, <name><surname>Ossei-Gerning</surname><given-names>N</given-names></name>, <name><surname>Carter</surname><given-names>A</given-names></name>, <name><surname>Mikkola</surname><given-names>H</given-names></name>, <name><surname>Grant</surname><given-names>PJ</given-names></name>. <article-title>Association of a common polymorphism in the factor XIII gene with myocardial infarction</article-title>. <source/>Thromb Haemost. <year>1998</year>;<volume>79</volume>(<issue>1</issue>): <fpage>8</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="pmid">9459313</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref061">
<label>61</label>
<mixed-citation publication-type="journal"><name><surname>Peyvandi</surname><given-names>F</given-names></name>, <name><surname>Tagliabue</surname><given-names>L</given-names></name>, <name><surname>Menegatti</surname><given-names>M</given-names></name>, <name><surname>Karimi</surname><given-names>M</given-names></name>, <name><surname>Komáromi</surname><given-names>I</given-names></name>, <name><surname>Katona</surname><given-names>E</given-names></name>, <etal>et al</etal>
<article-title>Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency</article-title>. <source/>Hum Mutat. <year>2004</year>;<volume>23</volume>(<issue>1</issue>): <fpage>98</fpage>.</mixed-citation>
</ref>
<ref id="pone.0172189.ref062">
<label>62</label>
<mixed-citation publication-type="journal"><name><surname>Katona</surname><given-names>É</given-names></name>, <name><surname>Muszbek</surname><given-names>L</given-names></name>, <name><surname>Devreese</surname><given-names>K</given-names></name>, <name><surname>Kovács</surname><given-names>KB</given-names></name>, <name><surname>Bereczky</surname><given-names>Z</given-names></name>, <name><surname>Jonkers</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Factor XIII deficiency: complete phenotypic characterization of two cases with novel causative mutations</article-title>. <source/>Haemophilia. <year>2014</year>;<volume>20</volume>(<issue>1</issue>): <fpage>114</fpage>–<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1111/hae.12267</pub-id>
<pub-id pub-id-type="pmid">24118344</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref063">
<label>63</label>
<mixed-citation publication-type="journal"><name><surname>Huber</surname><given-names>M</given-names></name>, <name><surname>Rettler</surname><given-names>I</given-names></name>, <name><surname>Bernasconi</surname><given-names>K</given-names></name>, <name><surname>Frenk</surname><given-names>E</given-names></name>, <name><surname>Lavrijsen</surname><given-names>SP</given-names></name>, <name><surname>Ponec</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Mutations of keratinocyte transglutaminase in lamellar ichthyosis</article-title>. <source/>Science. <year>1995</year>;<volume>267</volume>(<issue>5197</issue>): <fpage>525</fpage>–<lpage>528</lpage>. <pub-id pub-id-type="pmid">7824952</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref064">
<label>64</label>
<mixed-citation publication-type="journal"><name><surname>Russell</surname><given-names>LJ</given-names></name>, <name><surname>DiGiovanna</surname><given-names>JJ</given-names></name>, <name><surname>Rogers</surname><given-names>GR</given-names></name>, <name><surname>Steinert</surname><given-names>PM</given-names></name>, <name><surname>Hashem</surname><given-names>N</given-names></name>, <name><surname>Compton</surname><given-names>JG</given-names></name>, <etal>et al</etal>
<article-title>Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis</article-title>. <source/>Nat Genet. <year>1995</year>;<volume>9</volume>(<issue>3</issue>): <fpage>279</fpage>–<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1038/ng0395-279</pub-id>
<pub-id pub-id-type="pmid">7773290</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref065">
<label>65</label>
<mixed-citation publication-type="journal"><name><surname>Cassidy</surname><given-names>AJ</given-names></name>, <name><surname>van Steensel</surname><given-names>MA</given-names></name>, <name><surname>Steijlen</surname><given-names>PM</given-names></name>, <name><surname>van Geel</surname><given-names>M</given-names></name>, <name><surname>van der Velden</surname><given-names>J</given-names></name>, <name><surname>Morley</surname><given-names>SM</given-names></name>, <etal>et al</etal>
<article-title>A homozygous missense mutation in TGM5 abolishes epidermal transglutaminase 5 activity and causes acral peeling skin syndrome</article-title>. <source/>Am J Hum Genet. <year>2005</year>;<volume>77</volume>(<issue>6</issue>): <fpage>909</fpage>–<lpage>917</lpage>. <pub-id pub-id-type="doi">10.1086/497707</pub-id>
<pub-id pub-id-type="pmid">16380904</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref066">
<label>66</label>
<mixed-citation publication-type="journal"><name><surname>Kharfi</surname><given-names>M</given-names></name>, <name><surname>El Fekih</surname><given-names>N</given-names></name>, <name><surname>Ammar</surname><given-names>D</given-names></name>, <name><surname>Jaafoura</surname><given-names>H</given-names></name>, <name><surname>Schwonbeck</surname><given-names>S</given-names></name>, <name><surname>van Steensel</surname><given-names>MA</given-names></name>, <etal>et al</etal>
<article-title>A missense mutation in TGM5 causes acral peeling skin syndrome in a Tunisian family</article-title>. <source/>J Invest Dermatol. <year>2009</year>;<volume>129</volume>(<issue>10</issue>): <fpage>2512</fpage>–<lpage>2515</lpage>. <pub-id pub-id-type="doi">10.1038/jid.2009.118</pub-id>
<pub-id pub-id-type="pmid">19440220</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref067">
<label>67</label>
<mixed-citation publication-type="journal"><name><surname>Van der Velden</surname><given-names>JJ</given-names></name>, <name><surname>van Geel</surname><given-names>M</given-names></name>, <name><surname>Nellen</surname><given-names>RG</given-names></name>, <name><surname>Jonkman</surname><given-names>MF</given-names></name>, <name><surname>McGrath</surname><given-names>JA</given-names></name>, <name><surname>Nanda</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Novel TGM5 mutations in acral peeling skin syndrome</article-title>. <source/>Exp Dermatol. <year>2015</year>;<volume>24</volume>(<issue>4</issue>): <fpage>285</fpage>–<lpage>289</lpage>
<pub-id pub-id-type="doi">10.1111/exd.12650</pub-id>
<pub-id pub-id-type="pmid">25644735</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref068">
<label>68</label>
<mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>JL</given-names></name>, <name><surname>Yang</surname><given-names>X</given-names></name>, <name><surname>Xia</surname><given-names>K</given-names></name>, <name><surname>Hu</surname><given-names>ZM</given-names></name>, <name><surname>Weng</surname><given-names>L</given-names></name>, <name><surname>Jin</surname><given-names>X</given-names></name>, <etal>et al</etal>
<article-title>TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing</article-title>. <source/>Brain. <year>2010</year>;<volume>133</volume>(<issue>12</issue>): <fpage>3510</fpage>–<lpage>3518</lpage>.<pub-id pub-id-type="pmid">21106500</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref069">
<label>69</label>
<mixed-citation publication-type="journal"><name><surname>Tennessen</surname><given-names>JA</given-names></name>, <name><surname>Madeoy</surname><given-names>J</given-names></name>, <name><surname>Akey</surname><given-names>JM</given-names></name>. <article-title>Signatures of positive selection apparent in a small sample of human exomes</article-title>. <source/>Genome Res. <year>2010</year>;<volume>20</volume>(<issue>10</issue>): <fpage>1327</fpage>–<lpage>1334</lpage>. <pub-id pub-id-type="doi">10.1101/gr.106161.110</pub-id>
<pub-id pub-id-type="pmid">20693481</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref070">
<label>70</label>
<mixed-citation publication-type="journal"><name><surname>Yi</surname><given-names>X</given-names></name>, <name><surname>Liang</surname><given-names>Y</given-names></name>, <name><surname>Huerta-Sanchez</surname><given-names>E</given-names></name>, <name><surname>Jin</surname><given-names>X</given-names></name>, <name><surname>Cuo</surname><given-names>ZX</given-names></name>, <name><surname>Pool</surname><given-names>JE</given-names></name>, <etal>et al</etal>
<article-title>Sequencing of 50 human exomes reveals adaptation to high altitude</article-title>. <source/>Science. <year>2010</year>;<volume>329</volume>(<issue>5987</issue>): <fpage>75</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1126/science.1190371</pub-id>
<pub-id pub-id-type="pmid">20595611</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref071">
<label>71</label>
<mixed-citation publication-type="journal"><name><surname>O'Roak</surname><given-names>BJ</given-names></name>, <name><surname>Deriziotis</surname><given-names>P</given-names></name>, <name><surname>Lee</surname><given-names>C</given-names></name>, <name><surname>Vives</surname><given-names>L</given-names></name>, <name><surname>Schwartz</surname><given-names>JJ</given-names></name>, <name><surname>Girirajan</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations</article-title>. <source/>Nat Genet. <year>2011</year>;<volume>43</volume>(<issue>6</issue>): <fpage>585</fpage>–<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/ng.835</pub-id>
<pub-id pub-id-type="pmid">21572417</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref072">
<label>72</label>
<mixed-citation publication-type="journal"><name><surname>Kryukov</surname><given-names>GV</given-names></name>, <name><surname>Pennacchio</surname><given-names>LA</given-names></name>, <name><surname>Sunyaev</surname><given-names>SR</given-names></name>. <article-title>Most Rare Missense Alleles Are Deleterious in Humans: Implications for Complex Disease and Association Studies</article-title>. <source/>Am J Hum Genet. <year>2007</year>;<volume>80</volume>: <fpage>727</fpage>–<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1086/513473</pub-id>
<pub-id pub-id-type="pmid">17357078</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref073">
<label>73</label>
<mixed-citation publication-type="journal"><name><surname>McKusick</surname><given-names>VA</given-names></name>. <article-title>Mendelian Inheritance in Man and its online version, OMIM</article-title>. <source/>Am J Hum Genet. <year>2007</year>; <volume>80</volume>(<issue>4</issue>): <fpage>588</fpage>–<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1086/514346</pub-id>
<pub-id pub-id-type="pmid">17357067</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref074">
<label>74</label>
<mixed-citation publication-type="journal"><name><surname>Robinson</surname><given-names>PN</given-names></name>, <name><surname>Mundlos</surname><given-names>S</given-names></name>. <article-title>The human phenotype ontology</article-title>. <source/>Clin Genet. <year>2010</year>; <volume>77</volume>(<issue>6</issue>): <fpage>525</fpage>–<lpage>534</lpage> (2010). <pub-id pub-id-type="doi">10.1111/j.1399-0004.2010.01436.x</pub-id>
<pub-id pub-id-type="pmid">20412080</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref075">
<label>75</label>
<mixed-citation publication-type="journal"><name><surname>Saunders</surname><given-names>CJ</given-names></name>, <name><surname>Miller</surname><given-names>NA</given-names></name>, <name><surname>Soden</surname><given-names>SE</given-names></name>, <name><surname>Dinwiddie</surname><given-names>DL</given-names></name>, <name><surname>Noll</surname><given-names>A</given-names></name>, <name><surname>Alnadi</surname><given-names>NA</given-names></name>, <etal>et al</etal>
<article-title>Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units</article-title>. <source/>Sci Transl Med. <year>2012</year>; <volume>4</volume>(<issue>154</issue>): <fpage>154ra135</fpage>
<pub-id pub-id-type="doi">10.1126/scitranslmed.3004041</pub-id>
<pub-id pub-id-type="pmid">23035047</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref076">
<label>76</label>
<mixed-citation publication-type="journal"><name><surname>Köhler</surname><given-names>S</given-names></name>, <name><surname>Doelken</surname><given-names>SC</given-names></name>, <name><surname>Mungall</surname><given-names>CJ</given-names></name>, <name><surname>Bauer</surname><given-names>S</given-names></name>, <name><surname>Firth</surname><given-names>HV</given-names></name>, <name><surname>Bailleul-Forestier</surname><given-names>I</given-names></name>, <etal>et al</etal>
<article-title>The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data</article-title>. <source/>Nucleic Acids Res. <year>2014</year>
<volume>42</volume>, <fpage>D966</fpage>–<lpage>D974</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt1026</pub-id>
<pub-id pub-id-type="pmid">24217912</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref077">
<label>77</label>
<mixed-citation publication-type="journal"><name><surname>Muszbek</surname><given-names>L</given-names></name>, <name><surname>Adany</surname><given-names>R</given-names></name>, <name><surname>Mikkola</surname><given-names>H</given-names></name>. <article-title>Novel aspects of blood coagulation factor XIII: I. Structure, distribution, activation, and function</article-title>. <source/>Crit Rev Clin Lab Sci. <year>1996</year>;<volume>33</volume>: <fpage>357</fpage>–<lpage>421</lpage>. <pub-id pub-id-type="doi">10.3109/10408369609084691</pub-id>
<pub-id pub-id-type="pmid">8922891</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref078">
<label>78</label>
<mixed-citation publication-type="journal"><name><surname>Rashida</surname><given-names>A</given-names></name>, <name><surname>Miloszewski</surname><given-names>KJA</given-names></name>. <article-title>Factor XIII Deficiency</article-title>. <source/>Br J Haematol. <year>2008</year>;<volume>107</volume>(<issue>3</issue>): <fpage>468</fpage>–<lpage>484</lpage>.</mixed-citation>
</ref>
<ref id="pone.0172189.ref079">
<label>79</label>
<mixed-citation publication-type="journal"><name><surname>Bernassola</surname><given-names>F</given-names></name>, <name><surname>Federici</surname><given-names>M</given-names></name>, <name><surname>Corazzari</surname><given-names>M</given-names></name>, <name><surname>Terrinoni</surname><given-names>A</given-names></name>, <name><surname>Hribal</surname><given-names>ML</given-names></name>, <name><surname>De Laurenzi</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient</article-title>. <source/>FASEB J. <year>2002</year>;<volume>16</volume>(<issue>11</issue>): <fpage>1371</fpage>–<lpage>1378</lpage>. <pub-id pub-id-type="doi">10.1096/fj.01-0689com</pub-id>
<pub-id pub-id-type="pmid">12205028</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref080">
<label>80</label>
<mixed-citation publication-type="journal"><name><surname>Yates</surname><given-names>CM</given-names></name>, <name><surname>Sternberg</surname><given-names>MJE</given-names></name>. <article-title>The Effects of Non-Synonymous Single Nucleotide Polymorphisms (nsSNPs) on Protein–Protein Interactions</article-title>. <source/>J Mol Biol. <year>2013</year>;<volume>425</volume>(<issue>21</issue>): <fpage>3949</fpage>–<lpage>3963</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2013.07.012</pub-id>
<pub-id pub-id-type="pmid">23867278</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref081">
<label>81</label>
<mixed-citation publication-type="journal"><name><surname>Gentile</surname><given-names>V</given-names></name>, <name><surname>Saydak</surname><given-names>M</given-names></name>, <name><surname>Chiocca</surname><given-names>EA</given-names></name>, <name><surname>Akande</surname><given-names>O</given-names></name>, <name><surname>Birckbichler</surname><given-names>PJ</given-names></name>, <name><surname>Lee</surname><given-names>KN</given-names></name>, <etal>et al</etal>
<article-title>Isolation and characterization of cDNA clones to mouse macrophage and human endothelial cell tissue transglutaminases</article-title>. <source/>J Biol Chem. <year>1991</year>;<volume>266</volume>: <fpage>478</fpage>–<lpage>483</lpage>. <pub-id pub-id-type="pmid">1670766</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref082">
<label>82</label>
<mixed-citation publication-type="journal"><name><surname>Kanchan</surname><given-names>K</given-names></name>, <name><surname>Ergülen</surname><given-names>E</given-names></name>, <name><surname>Király</surname><given-names>R</given-names></name>, <name><surname>Simon-Vecsei</surname><given-names>Z</given-names></name>, <name><surname>Fuxreiter</surname><given-names>M</given-names></name>, <name><surname>Fésüs</surname><given-names>L</given-names></name>. <article-title>Identification of a specific one amino acid change in recombinant human transglutaminase 2 that regulates its activity and calcium sensitivity</article-title>. <source/>Biochem J. <year>2013</year>;<volume>455</volume>: <fpage>261</fpage>–<lpage>272</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20130696</pub-id>
<pub-id pub-id-type="pmid">23941696</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref083">
<label>83</label>
<mixed-citation publication-type="journal"><name><surname>Van der Lee</surname><given-names>R</given-names></name>, <name><surname>Buljan</surname><given-names>M</given-names></name>, <name><surname>Lang</surname><given-names>B</given-names></name>, <name><surname>Weatheritt</surname><given-names>RJ</given-names></name>, <name><surname>Daughdrill</surname><given-names>GW</given-names></name>, <name><surname>Dunker</surname><given-names>AK</given-names></name>, <etal>et al</etal>
<article-title>Classification of intrinsically disordered regions and proteins</article-title>. <source/>Chem Reviews. <year>2014</year>; <volume>114</volume>(<issue>13</issue>): <fpage>6589</fpage>–<lpage>6631</lpage>.</mixed-citation>
</ref>
<ref id="pone.0172189.ref084">
<label>84</label>
<mixed-citation publication-type="journal"><name><surname>Gfeller</surname><given-names>D</given-names></name>, <name><surname>Ernst</surname><given-names>A</given-names></name>, <name><surname>Jarvik</surname><given-names>N</given-names></name>, <name><surname>Sidhu</surname><given-names>SS</given-names></name>, <name><surname>Bader</surname><given-names>GD</given-names></name>. <article-title>Prediction and experimental characterization of nsSNPs altering human PDZ-binding motifs</article-title>. <source/>PLoS One. <year>2014</year>;<volume>9</volume>(<issue>4</issue>): <fpage>e94507</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0094507</pub-id>
<pub-id pub-id-type="pmid">24722214</pub-id></mixed-citation>
</ref>
<ref id="pone.0172189.ref085">
<label>85</label>
<mixed-citation publication-type="journal"><name><surname>Uyar</surname><given-names>B</given-names></name>, <name><surname>Weatheritt</surname><given-names>RJ</given-names></name>, <name><surname>Dinkel</surname><given-names>H</given-names></name>, <name><surname>Davey</surname><given-names>NE</given-names></name>, <name><surname>Gibson</surname><given-names>TJ</given-names></name>. <article-title>Proteome-wide analysis of human disease mutations in short linear motifs: neglected players in cancer?</article-title>
<source/>Mol BioSystems
<year>2014</year>;<volume>10</volume>(<issue>10</issue>): <fpage>2626</fpage>–<lpage>2642</lpage>.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>